STOCK TITAN

NervGen Pharma posts C$2.47M nine-month net income

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

NERVGEN PHARMA CORP. (NGEN) reported a C$6.41 million net loss for the three months ended September 30, 2026, compared with a restated C$4.72 million loss a year earlier. For the nine months, it recorded C$2.47 million of net income versus a restated C$17.72 million loss, primarily because of a C$33.89 million non-cash gain from remeasuring warrant derivatives. 2025 comparative statements were restated to correct errors in warrant-derivative valuation and stock-based compensation.

Nine-month research and development expenses were C$20.48 million, up from C$9.93 million, with costs linked to starting a Phase 3 NVG-291 trial in chronic tetraplegia, manufacturing and toxicology work. Net cash used in operating activities was C$27.02 million, compared with C$13.10 million. Cash and equivalents were C$80.12 million at September 30; management believes that balance is sufficient to fund operations for at least 12 months from September 30 and the statements’ issuance date.

The May underwritten offering sold 24 million units for gross proceeds of C$82.9 million (US$60.0 million). NERVGEN is pre-revenue and expects losses and negative operating cash flow to continue as it advances research and development.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

How the balance works

Positive

  • Moderate pointNine-month results reached C$2.47 million net income, including a C$33.89 million non-cash warrant gain.

Negative

  • Moderate pointOperating cash used was C$27.02 million, compared with C$13.10 million a year earlier.
  • Minor pointQuarterly net loss widened to C$6.41 million from C$4.72 million.

Filing Explained

The US$50 million ATM program had no share sales through September 30, 2026, so that qualified amount remained issuance capacity rather than shares already issued.

Form 6-K is a foreign private issuer’s interim report; this filing identifies the 24 million units sold in the May offering, each with one common share and one warrant. All 24 million May warrants remained outstanding at September 30, 2026, and each can be exercised for one additional share at US$3.68 through May 22, 2031; exercise would increase the share count and reduce existing holders’ percentage ownership, absent offsets.

The July 2, 2026 supplement qualified up to US$50 million of common shares for gradual sales through an agent at prevailing Nasdaq prices, the structure of an at-the-market program. The filing reports no shares sold under that program through September 30, 2026; the stated ceiling is issuance capacity, not shares already issued.

Quarterly net loss C$6.41 million Three months ended September 30, 2026; restated prior-year quarter loss was C$4.72 million.
Nine-month net income C$2.47 million Nine months ended September 30, 2026; included a C$33.89 million non-cash warrant derivative gain.
Research and development expenses C$20.48 million Nine months ended September 30, 2026, compared with C$9.93 million in 2025.
Cash used in operating activities C$27.02 million Nine months ended September 30, 2026, compared with C$13.10 million in 2025.
Cash and cash equivalents C$80.12 million As of September 30, 2026.
May 2026 offering gross proceeds C$82.9 million (US$60.0 million) Underwritten offering of 24 million units on May 22, 2026.
2026 ATM program capacity Up to US$50 million Common shares qualified for distribution under the program filed July 2, 2026.
Warrant derivative liability C$34.62 million Fair value as of September 30, 2026; the company described it as non-cash.
warrant derivative financial
"fair value of the warrant derivative"
A warrant derivative is a tradable financial instrument that gives its holder the right, but not the obligation, to buy (or sometimes sell) a company’s stock at a set price within a specified time period. Think of it like a coupon that lets you purchase shares later at a pre-agreed price; because it magnifies gains or losses relative to owning the stock, it provides leverage and can change a company’s share count if exercised. Investors watch warrants for their potential to amplify returns, introduce dilution when converted, and to affect overall market supply for the underlying shares.
Black-Scholes valuation model financial
"uses the Black-Scholes valuation model to estimate fair value"
at-the-market equity program financial
"under an at-the-market equity program"
An at-the-market equity program lets a company sell newly issued shares directly into the open market at the current trading price through a broker, rather than in a single, prearranged block. It provides flexible, on-demand access to cash—like drawing small amounts from a credit line—but increases the number of shares outstanding, which can reduce existing shareholders’ ownership percentage and put downward pressure on the stock price, so investors monitor program size and pacing.
working capital financial
"working capital (a non-GAAP measure defined as current assets less current liabilities)"
Working capital is the money a business has available to cover its daily expenses, like paying bills and buying supplies. It’s like the cash in your wallet that helps you handle everyday costs; having enough ensures the business can operate smoothly without running into money shortages.
Fast Track designation regulatory
"NVG-291 has been granted Fast Track designation by the FDA"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
Orphan Drug Designation regulatory
"Orphan Drug Designation from the EMA"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were NGEN’s third-quarter and nine-month results in 2026?

NGEN reported a C$6.41 million net loss for the three months ended September 30, 2026, and C$2.47 million net income for the nine months. The nine-month result primarily reflected a C$33.89 million non-cash gain from remeasuring warrant derivatives.

How much can NGEN raise through its 2026 ATM program, and has it sold shares under it?

The 2026 at-the-market program qualifies the distribution of up to US$50 million in common shares. NGEN reported that it issued and sold zero shares under the program during the nine months ended September 30, 2026.

What payment did NGEN’s post-quarter clinical milestone trigger?

A clinical development milestone achieved after September 30, 2026 triggered a US$250,000 payment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission File Number: 001-43048

 

NERVGEN PHARMA CORP.

(Exact name of Registrant as specified in its charter)

 

N/A
(Translation of Registrant’s name)

 

1200 Brickell Avenue, Suite 1950 #IP 1346
Miami, Florida 33131
Telephone: (778) 731-1711

(Address and telephone number of registrant’s principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ¨   Form 40-F x

 

 

 

 

 

 

INCORPORATION BY REFERENCE

 

Exhibits 99.1 and 99.2 of this Report on Form 6-K are incorporated by reference into the Registrant’s Registration Statement on Form F-10 (File No. 333-296217) and the Registrant’s Registration Statements on Form S-8 (File Nos. 333-292927 and 333-295632), to be a part thereof from the date on which this Report on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

DOCUMENTS INCLUDED AS PART OF THIS REPORT

 

Exhibit  
   
99.1 Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2026 and 2025.
99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three and nine months ended September 30, 2026.
99.3 Form 52-109F2 Certification of Interim Filings by CEO.
99.4 Form 52-109F2 Certification of Interim Filings by CFO.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  NERVGEN PHARMA CORP.
     
Date: November 16, 2026 By: /s/ Keith Vendola
    Name: Keith Vendola
    Title: Chief Financial Officer

 

 

 

 

Exhibit 99.1

 

 

Condensed consolidated interim financial statements of

 

NERVGEN PHARMA CORP.

 

(Expressed in Canadian Dollars - Unaudited)

 

For the three months and nine months ended September 30, 2026 and 2025

 

 

 

 

NERVGEN PHARMA CORP.
Condensed Consolidated Interim Statements of Financial Position
(Expressed in Canadian dollars)
(Unaudited)
         
as at  September 30, 2026   December 31, 2025 
Assets          
Current assets          
Cash and cash equivalents   80,119,909    22,069,635 
Receivables (Note 9)   111,953    80,825 
Prepaids, deposits, and other current assets (Note 8)   4,153,613    641,649 
Current portion of net investment in lease (Note 10)   -    8,369 
Deferred share issuance costs (Note 6)   323,279    - 
    84,708,754    22,800,478 
Non-current assets          
Intangible asset (Note 11)   367,317    409,163 
    367,317    409,163 
    85,076,071    23,209,641 
           
Liabilities          
Current liabilities          
Accounts payable and accrued liabilities (Notes 12 and 13)   6,676,251    4,657,448 
Warrant derivative (Note 14)   34,623,326    12,647,514 
Current portion of lease liability (Note 10)   -    8,369 
    41,299,577    17,313,331 
           
Shareholders’ Equity          
Common shares (Note 15)   144,367,915    106,905,846 
Reserves (Note 16)   39,104,990    41,155,771 
Deficit   (139,696,411)   (142,165,307)
    43,776,494    5,896,310 
    85,076,071    23,209,641 

 

Nature of business (Note 1)        
Commitments (Note 17)        
Subsequent events (Note 19)        
         
Approved by the Board        
         
/s/ Adam Rogers Director   /s/ Neil A. Klompas Director
         
The accompanying notes are an integral part of these condensed consolidated interim financial statements

 

2 

 

 

NERVGEN PHARMA CORP.        
Condensed Consolidated Interim Statements of Income (Loss) and Comprehensive Income (Loss)        
(Expressed in Canadian dollars)        
(Unaudited)        
         
   For the
Three Months
   For the
Three Months
Ended
   For the
Nine Months
   For the
Nine Months
Ended
 
   Ended   September 30, 2025   Ended   September 30, 2025 
   September 30, 2026   (Restated – see Note 4)   September 30, 2026   (Restated – see Note 4) 
   $   $   $   $ 
Operating expenses                    
Research and development (Note 18)   7,900,136    4,264,566    20,476,128    9,934,349 
General and administrative (Note 18)   3,287,750    1,296,146    9,830,493    7,231,511 
Total operating expenses   11,187,886    5,560,712    30,306,621    17,165,860 
                     
Interest income   (581,415)   (77,071)   (865,931)   (271,736)
Share issuance costs allocated to warrant derivative (Note 15)   -    -    3,920,232    - 
Unrealized loss (gain) on warrant derivative (Note 14)   (4,438,926)   (811,274)   (33,890,843)   740,302 
Foreign exchange loss (gain)   240,948    45,908    (1,938,975)   88,155 
Net income (loss) and comprehensive income (loss)   (6,408,493)   (4,718,275)   2,468,896    (17,722,581)
                     
Basic net income (loss) per share (Note 15)   (0.06)   (0.06)   0.03    (0.25)
 Diluted net loss per share (Note 15)   (0.06)   (0.07)   (0.08)   (0.25)
                     
Weighted average Common Shares outstanding - basic   107,455,028    73,162,932    93,528,372    71,937,943 
                     
Weighted average Common Shares outstanding – diluted (Note 15)   107,455,028    74,735,138    93,892,724    71,937,943 

 

3 

 

 

NERVGEN PHARMA CORP.
Condensed Consolidated Interim Statements of Cash Flows
(Expressed in Canadian dollars)
(Unaudited)
       Nine Months 
       Ended 
   Nine Months
Ended
September 30, 2026
   September 30, 2025
(Restated – see
Note 4)
 
   $   $ 
Operating Activities          
Net income (loss) for the period   2,468,896    (17,722,581)
Items not involving cash:          
Amortization of intangible asset (Note 11)   41,846    41,846 
Interest expense on lease liability (Note 10)   42    3,316 
Interest income on net investment in lease (Note 10)   (42)   (3,316)
Stock-based compensation (Note 16)   4,349,008    3,083,270 
Unrealized foreign exchange   (2,042,588)   (94,778)
Change in fair value of warrant derivative (Note 14)   (33,890,843)   740,302 
Share issuance costs allocated to warrant derivative (Note 15)   3,920,232    - 
Changes in non-cash working capital:          
Receivables (Note 9)   (31,128)   71,096 
Prepaid expenses and deferred costs (Note 8)   (3,835,243)   320,017 
Accounts payable and accrued liabilities (Note 12, 13)   2,001,120    459,046 
    (27,018,700)   (13,101,782)
Investing Activities          
Payments received from net investment in lease (Note 10)   8,411    75,695 
    8,411    75,695 
Financing Activities          
Repayment of lease liability (Note 10)   (8,411)   (75,695)
Gross proceeds from issuance of common shares and warrants (Note 15)   82,876,284    2,774,227 
Share issuance costs – cash (Note 15)   (5,857,918)   (685,344)
Proceeds from warrant and option exercises (Note 15 and 16)   5,990,338    5,008,876 
    83,000,293    7,022,064 
           
Effect of foreign exchange on cash and cash equivalents   2,060,270    100,589 
           
Net increase (decrease) in cash and cash equivalents   58,050,274    (5,903,434)
Cash and cash equivalents, beginning of period   22,069,635    17,267,489 
Cash and cash equivalents, end of period   80,119,909    11,364,055 
           
Cash paid for interest and taxes  $-   $- 
Non-cash transactions:          
Fair value of options allocated to share capital upon exercise   5,829,408    1,554,741 
Fair value of warrants allocated to share capital upon exercise   129,045    269,543 

 

The accompanying notes are an integral part of these condensed consolidated interim financial statements

 

4 

 

 

NERVGEN PHARMA CORP.
Condensed Consolidated Interim Statements of Changes in Shareholders' Equity
(Expressed in Canadian dollars)                    
(Unaudited)                    
                     
   Common Shares             
       Amount   Reserves   Deficit   Total 
   Number   $   $   $   $ 
Balance December 31, 2024   70,333,149    83,916,111    20,304,260    (97,950,974)   6,269,397 
Common share financings, net (Note 15)   949,700    2,088,883    -    -    2,088,883 
Warrant exercise (Note 15 and 16)   925,441    3,028,339    (269,543)   -    2,758,796 
Option exercises - Restated (Note 4, 15 and 16)   1,199,503    3,804,821    (1,554,741)   -    2,250,080 
Stock-based compensation - Restated (Note 4 and 16)   -    -    3,083,270    -    3,083,270 
Net loss and comprehensive loss – Restated   -    -    -    (17,722,581)   (17,722,581)
Balance September 30, 2025 - Restated   73,407,793    92,838,154    21,563,246    (115,673,555)   (1,272,155)
                          
Balance December 31, 2025   79,649,257    106,905,846    41,155,771    (142,165,307)   5,896,310 
May 2026 Public Offering, net (Note 15)   24,000,000    25,065,908    -    -    25,065,908 
At-the-market Program, net (Note 15)   245    (48,890)   -    -    (48,890)
Warrant exercises (Note 15 and 16)   357,422    1,153,126    (74,101)   -    1,079,025 
Option exercises (Note 15 and 16)   3,509,991    10,795,645    (5,829,408)   -    4,966,237 
Restricted and performance share units vested (Note 16)   99,497    496,280    (496,280)   -    - 
Stock-based compensation (Note 16)   -    -    4,349,008    -    4,349,008 
Net income and comprehensive income   -    -    -    2,468,896    2,468,896 
Balance September 30, 2026   107,616,412    144,367,915    39,104,990    (139,696,411)   43,776,494 

 

The accompanying notes are an integral part of these condensed consolidated interim financial statements

 

5 

 

 

NERVGEN PHARMA CORP.

Notes to the condensed consolidated interim financial statements (unaudited)

For the three and nine months ended September 30, 2026 and 2025

(Expressed in Canadian Dollars)

 

1.Nature of business

 

NervGen Pharma Corp. (the “Company” or “NervGen”) is a publicly traded biotechnology company incorporated on January 19, 2017, under the Business Corporations Act (British Columbia). The Principal Executive Office of the Company is located at 1200 Brickell Avenue, Suite 1950 #IP 1346 Miami, FL 33131, and the registered office is located at 1133 Melville Street, Suite 3500, The Stack, Vancouver, BC, V6E 4E5, Canada.

 

Common Shares in the capital of NervGen (the “Common Shares”) trade on the Nasdaq Capital Market under the symbol “NGEN”.

 

The Company has two wholly owned subsidiaries: NervGen US Inc. incorporated in the State of Delaware on June 11, 2018, and NervGen Australia Pty Ltd. registered in Queensland on December 8, 2020.

 

The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for traumatic and neurologic disorders. NervGen’s initial target indication is spinal cord injury (“SCI”).

 

2.Basis of presentation

 

a)Basis of measurement and statement of compliance

 

These condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standards (“IAS”) 34 ‘Interim Financial Reporting’ (IAS 34) using the same accounting policies as detailed in the Company’s annual audited consolidated financial statements for the year ended December 31, 2025. These condensed consolidated interim financial statements do not include all of the information required for full annual financial statements in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). The Company’s operations are not subject to seasonal or cyclical fluctuations; expenditures vary with the timing of research and development activities.

 

The condensed consolidated interim financial statements have been prepared on a historical cost basis except for certain financial assets and financial liabilities measured at fair value. In addition, these condensed consolidated interim financial statements have been prepared using the accrual basis of accounting, except for cash flow information. These condensed consolidated interim financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2025.

 

The condensed consolidated interim financial statements were approved by the Company’s board of directors (the “Board of Directors”) and authorized for issue on November 16, 2026.

 

b)Going Concern

 

These condensed consolidated interim financial statements have been prepared in accordance with IFRS accounting principles applicable to a going concern using the historical cost basis.

 

Management has forecasted that the Company’s existing working capital is sufficient to operate the Company for at least the next 12 months from September 30, 2026 and from the date of issuance of these financial statements. The Company is in pre-revenue stage and no revenues are expected in the foreseeable future. The Company’s future operations are dependent on successful development and commercialization of pharmaceutical products, as well as its ability to secure additional financing as needed. While the Company has been successful in the past in obtaining financing, there can be no assurance that the Company will be able to obtain adequate financing, or that such financing will be on terms acceptable to the Company, to meet future operational needs which may result in the delay, reduction, or discontinuation of ongoing development programs.

 

NERVGEN PHARMA CORP. Q3 2026 INTERIM FINANCIAL STATEMENTS 6 

 

 

NERVGEN PHARMA CORP.

Notes to the condensed consolidated interim financial statements (unaudited)

For the three and nine months ended September 30, 2026 and 2025

(Expressed in Canadian Dollars)

 

2.Basis of presentation cont’d

 

c)Principles of Consolidation

 

These condensed consolidated interim financial statements include the accounts of the Company and its wholly-owned subsidiaries NervGen US Inc. and NervGen Australia Pty Ltd. The subsidiaries are fully consolidated from the date at which control is determined to have occurred and are deconsolidated from the date that the Company no longer controls the entity. Intercompany transactions, balances, and gains and losses on transactions between subsidiaries are eliminated.

 

d)Functional and presentation currency

 

The functional currency of an entity is the currency of the primary economic environment in which the entity operates. The functional currency of NervGen and its subsidiaries is the Canadian dollar. Transactions in foreign currencies are translated to the functional currency at the rate on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies are retranslated at the spot rate of exchange as at the reporting date. All differences are taken to profit or loss. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate as at the date of the initial transaction. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rate at the date when the fair value was determined.

 

e)Significant accounting judgments, estimates and assumptions

 

The preparation of these condensed consolidated interim financial statements in accordance with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated interim financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

The condensed consolidated interim financial statements include estimates, which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the condensed consolidated interim financial statements and may require accounting adjustments based on future occurrences. The estimates and underlying assumptions are reviewed on a regular basis. Revisions to accounting estimates are accounted for prospectively.

 

The key judgments and assumptions concerning the future, and other key sources of estimation uncertainty, as of the date of the condensed consolidated interim statement of financial position, that have a significant risk of causing material adjustment to the carrying amounts of assets and liabilities within the next fiscal year arise in connection with the going concern assessment, valuation of intangible assets, recognition of government assistance, valuation of warrant derivative, stock-based compensation, contingent repayment of grant funding, clinical accruals, and the determination of the functional currency of the Company.

 

3.Material accounting policies

 

The accounting policies applied in these condensed consolidated interim financial statements are the same as those applied in the Company’s audited consolidated financial statements for the year ended December 31, 2025.

 

NERVGEN PHARMA CORP. Q3 2026 INTERIM FINANCIAL STATEMENTS 7 

 

 

NERVGEN PHARMA CORP.

Notes to the condensed consolidated interim financial statements (unaudited)

For the three and nine months ended September 30, 2026 and 2025

(Expressed in Canadian Dollars)

 

4.Restatement of Prior Period Financial Statements

 

The comparative figures for the three and nine months ended September 30, 2025 have been restated to correct errors in the valuation of warrant derivative liabilities and stock-based compensation, as described in Note 4 of the Company’s restated audited consolidated financial statements for the year ended December 31, 2025, filed on October 16, 2026. The effect of the restatement on each affected line item of the comparative periods presented is summarized below:

 

Condensed Consolidated Interim Statements of Income (Loss) and Comprehensive Income (Loss)

for the three months ended September 30, 2025

 

   As Previously
Stated
   Restatement
Adjustments
   As Restated 
Operating expenses               
Research and development (Note 18)   4,444,224    (179,658)   4,264,566 
General and administrative (Note 18)   1,726,463    (430,317)   1,296,146 
Total operating expenses   6,170,687    (609,975)   5,560,712 
Interest income   (77,071)   -    (77,071)
Unrealized loss (gain) on warrant derivative (Note 14)   (1,983,455)   1,172,181    (811,274)
Foreign exchange loss (gain)   45,909    (1)   45,908 
Net income (loss) and comprehensive income (loss)   (4,156,070)   (562,205)   (4,718,275)
Basic net income (loss) per share   (0.06)   -    (0.06)
Diluted net income (loss) per share   (0.06)   (0.01)   (0.07)
Weighted average Common Shares outstanding (Note 15)   73,162,932    -    73,162,932 

 

for the nine months ended September 30, 2025

 

   As Previously
Stated
   Restatement
Adjustments
   As Restated 
Operating expenses               
Research and development (Note 18)   10,303,596    (369,247)   9,934,349 
General and administrative (Note 18)   8,371,373    (1,139,862)   7,231,511 
Total operating expenses   18,674,969    (1,509,109)   17,165,860 
Interest income   (271,736)   -    (271,736)
Unrealized loss (gain) on warrant derivative (Note 14)   (1,282,940)   2,023,242    740,302 
Foreign exchange loss (gain)   88,156    (1)   88,155 
Net income (loss) and comprehensive income (loss)   (17,208,449)   (514,132)   (17,722,581)
Basic net income (loss) per share   (0.24)   (0.01)   (0.25)
Diluted net income (loss) per share   (0.24)   (0.01)   (0.25)
Weighted average Common Shares outstanding (Note 15)   71,937,943    -    71,937,943 

 

Condensed Consolidated Interim Statements of Cash Flows

for the nine months ended September 30, 2025

 

   As Previously
Stated
   Restatement
Adjustments
   As Restated 
Operating Activities               
Net income (loss) for the period   (17,208,449)   (514,132)   (17,722,581)
Stock-based compensation   4,592,380    (1,509,110)   3,083,270 
Change in fair value of warrant derivative (Note 14)   (1,282,940)   2,023,242    740,302 
Other items not involving cash and changes in non-cash working capital   797,227    -    797,227 
Net cash used in operating activities   (13,101,782)   -    (13,101,782)

 

NERVGEN PHARMA CORP. Q3 2026 INTERIM FINANCIAL STATEMENTS 8 

 

 

NERVGEN PHARMA CORP.

Notes to the condensed consolidated interim financial statements (unaudited)

For the three and nine months ended September 30, 2026 and 2025

(Expressed in Canadian Dollars)

 

4.Restatement of Prior Period Financial Statements cont’d

 

Condensed Consolidated Interim Statements of Changes in Shareholders’ Equity

for the nine months ended September 30, 2025

 

   As Previously
Stated
   Restatement
Adjustments
   As Restated 
Total Shareholders’ Equity               
Balance December 31, 2024   2,576,607    3,692,790    6,269,397 
Common share financings, net (Note 15)   2,088,883    -    2,088,883 
Warrant exercises (Note 16)   2,758,796    -    2,758,796 
Option exercises (Note 16)   2,250,080    -    2,250,080 
Stock-based compensation (Note 16)   4,592,381    (1,509,111)   3,083,270 
Income (loss) and comprehensive income (loss)   (17,208,449)   (514,132)   (17,722,581)
Balance September 30, 2025   (2,941,703)   1,669,548    (1,272,155)

 

5.Segment reporting

 

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses. The Company has one reportable operating segment being the research and development of pharmaceutical drugs. The measure of segment profit or loss is net income (loss), as presented in the condensed consolidated interim statements of income (loss) and comprehensive income (loss). Total assets and total liabilities of the segment are as presented in the condensed consolidated interim statements of financial position. The Company’s intangible assets are registered in the U.S., and as of September 30, 2026, the Company had cash and other current assets of approximately US$53,019,600 (CA$75,156,051) (December 31, 2025 - US$3,833,348, CA$5,238,386), in the U.S. As of September 30, 2026, the Company also had other current assets of approximately AU$421,222 (CA$417,346) (December 31, 2025 - AU$531,664, CA$486,313) held in Australia. All other assets are held in Canada.

 

6.Capital disclosures

 

The Company defines its capital as share capital, warrants, retention securities, options, restricted share units, and performance share units. The Company’s objectives, when managing capital, are to safeguard cash as well as maintain financial liquidity and flexibility in order to preserve its ability to meet financial obligations and deploy capital to grow its businesses.

 

The Company’s financial strategy is designed to maintain a flexible capital structure consistent with the objectives stated above and to respond to business growth opportunities and changes in economic conditions. In order to maintain or adjust its capital structure, the Company may issue shares or issue debt (secured, unsecured, convertible and/or other types of available debt instruments).

 

On November 25, 2024, the Company filed a short form base shelf prospectus, which was subsequently restated on December 15, 2025 and amended on May 22, 2026 (the "Base Shelf") that qualifies for distribution of up to US$250,000,000 of Common Shares, debt securities, subscription receipts, warrants and units comprised of one or more of the other securities described. The Base Shelf amends the Company’s previous base shelf and is also registered with the U.S. Securities and Exchange Commission on Form F-10 that was filed on May 26, 2026 (the Form F-10 and the Base Shelf referred to herein collectively as the “Base Shelf”). Under the Base Shelf, the Company may sell securities to or through underwriters, dealers, placement agents, or other intermediaries, and also may sell securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying prospectus supplement.

 

The Base Shelf provides the Company with additional flexibility when managing its cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in the Company. The Company expects that the Base Shelf will be effective until December 25, 2026.

 

NERVGEN PHARMA CORP. Q3 2026 INTERIM FINANCIAL STATEMENTS 9 

 

 

NERVGEN PHARMA CORP.

Notes to the condensed consolidated interim financial statements (unaudited)

For the three and nine months ended September 30, 2026 and 2025

(Expressed in Canadian Dollars)

 

6.Capital disclosures cont’d

 

On July 2, 2026, the Company filed a prospectus supplement that, together with the Base Shelf, qualified the distribution of Common Shares, under an at-the-market equity program (the “2026 ATM Program”) that allows the Company to issue and sell Common Shares to the public from time to time through an agent (the “Agent”), at the Company’s discretion and subject to regulatory requirements. All Common Shares sold under the 2026 ATM Program will be sold through the Nasdaq, at the prevailing market price at the time of sale. As Common Shares distributed under the 2026 ATM Program are issued and sold at the prevailing market prices at the time of their sale, prices may vary among purchasers and during the period of distribution. During the nine months ended September 30, 2026, the Company issued and sold zero Common Shares under the 2026 ATM Program, and incurred $323,279 of legal expenses and professional fees in connection with setting up the 2026 ATM Program.

 

The Company will use the net proceeds from the 2026 ATM Program principally for general corporate purposes (including funding ongoing operations and/or working capital requirements), to repay indebtedness outstanding from time to time, to fund research and development, intellectual property development, and preclinical and clinical expenses.

 

There were no changes to the Company’s capital management policy during the nine months ended September 30, 2026. The Company is not subject to any externally imposed capital requirements.

 

7.Financial risk management

 

(a)Fair value

 

The Company’s financial instruments recognized on the condensed consolidated interim statements of financial position consist of cash and cash equivalents, receivables, warrant derivative, accounts payable and accrued liabilities. The fair value of cash and cash equivalents, receivables, accounts payable and accrued liabilities approximate their carrying values due to their short-term maturity.

 

(b)Classification of financial instruments

 

The Company’s financial instruments, recorded at fair value, require disclosure about how the fair value was determined based on significant levels of inputs described in the following hierarchy:

 

Level 1 - Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions occur in sufficient frequency and value to provide pricing information on an ongoing basis.

 

Level 2 - Pricing inputs are other than quoted prices in active markets included in Level 1. Prices in Level 2 are either directly or indirectly observable as of the reporting date. Level 2 valuations are based on inputs including quoted forward prices for commodities, time value and volatility factors, which can be substantially observed or corroborated in the marketplace.

 

Level 3 - Valuations in this level are those with inputs for the asset or liability that are not based on observable market data.

 

Cash and cash equivalents are measured at fair value using Level 1 as the basis for measurement in the fair value. The recorded amounts for receivables, accounts payable, and accrued liabilities, approximate their fair value due to their short-term nature. In July 2022, November 2025, and May 2026, the Company issued common share purchase warrants with an exercise price denominated in a currency that differs from the Company’s functional currency, which are treated as a derivative measured at fair value with subsequent changes in fair value accounted for through the condensed consolidated interim statements of income (loss) and comprehensive income (loss). The warrants issued in July 2022 were subsequently amended in December 2025 to have an exercise price denominated in the Company’s functional currency resulting in a reclassification of the warrant as an equity classified instrument at the fair value determined on the date of the amendment. The November 2025 and May 2026 warrants remain liability classified as of September 30, 2026, and the fair value of the corresponding warrant derivative recognized on the consolidated statements of financial position is based on Level 2 inputs (significant observable inputs) as these warrants have not been listed on an exchange and therefore do not trade on an active market. As of September 30, 2026, the fair value of the Company’s non-cash warrant derivative was $34.6 million (December 31, 2025 - $12.6 million). The Company uses the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Common Share historical volatility, the risk-free interest rate is based on Federal Reserve Bank of St. Louis benchmark treasury yield rates and the expected life represents the estimated length of time the warrants are expected to remain outstanding.

 

NERVGEN PHARMA CORP. Q3 2026 INTERIM FINANCIAL STATEMENTS 10 

 

 

NERVGEN PHARMA CORP.

Notes to the condensed consolidated interim financial statements (unaudited)

For the three and nine months ended September 30, 2026 and 2025

(Expressed in Canadian Dollars)

 

7.Financial risk management cont’d

 

The Company has exposure to the following risks from its use of financial instruments: credit, liquidity, currency, and interest rate risk. The Company reviews its risk management framework on a quarterly basis and makes adjustments as necessary. There have been no significant changes in these risk exposures compared to December 31, 2025.

 

(c)Credit risk

 

Credit risk is the risk of potential loss if a counterparty to a financial instrument fails to meet its contractual obligations. The Company’s credit risk is primarily attributable to its liquid financial assets, including cash and cash equivalents, receivables, deposits, and balances receivable from the government. The Company limits the exposure to credit risk in its cash and cash equivalents by only holding its cash and cash equivalents with high-credit quality financial institutions in business and/or savings accounts.

 

(d)Liquidity risk

 

Liquidity risk is the risk that the Company will not have the resources to meet its obligations as they fall due. The Company manages this risk by closely monitoring cash forecasts and managing resources to ensure that the Company will have sufficient liquidity to meet its obligations. All of the Company’s financial liabilities are classified as current and the majority, other than the non-cash warrant derivative, are anticipated to mature within the next ninety days. Other than the non-cash warrant derivative, the Company is exposed to liquidity risk on its financial liabilities.

 

(e)Market Risk

 

a.Currency risk

 

The Company has identified its functional currency as the Canadian dollar. Transactions are transacted in Canadian dollars, U.S. dollars and in Australian dollars. Fluctuations in the U.S. or Australian dollar exchange rate could have a significant impact on the Company’s results. Assuming all other variables remain constant, a 10% depreciation or appreciation of the Canadian dollar against the U.S. dollar would result in an increase or decrease in net income (loss) and comprehensive income (loss) for the nine months ended September 30, 2026, of $7.2 million (September 30, 2025 - $0.1 million). A 10% depreciation or appreciation of the Canadian dollar against the Australian dollar would result in an increase or decrease in net income (loss) and comprehensive income (loss) for the nine months ended September 30, 2026, of $0.2 million (September 30, 2025 - $0.1 million).

 

In the near-term, the Company mitigates overall currency risk through the use of U.S. dollar denominated cash balances to pay forecasted U.S. denominated expenses when possible. In the long-term, the Company is exposed to net currency risk from employee costs as well as the purchase of goods and services in the United States and Australia.

 

Balances in U.S. dollars are as follows:

 

   September 30, 2026   December 31, 2025 
   US$   US$ 
Cash   51,074,348    9,695,348 
Receivables   75,390    47,275 
Vendor deposits   2,662,670    134,503 
Accounts payable and accrued liabilities   (3,062,685)   (1,331,795)
    50,749,721    8,545,331 

 

NERVGEN PHARMA CORP. Q3 2026 INTERIM FINANCIAL STATEMENTS 11 

 

 

NERVGEN PHARMA CORP.

Notes to the condensed consolidated interim financial statements (unaudited)

For the three and nine months ended September 30, 2026 and 2025

(Expressed in Canadian Dollars)

 

7.Financial risk management cont’d

 

Balances in Australian dollars are as follows:

 

   September 30, 2026   December 31, 2025 
   AU$   AU$ 
Cash   420,134    529,628 
Receivables   1,087    2,036 
Accounts payable and accrued liabilities   (2,026,906)   (2,009,171)
    (1,605,685)   (1,477,507)

 

b.Interest rate risk

 

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The warrant derivative that is discussed further in Note 14 is recorded at fair value using a Black-Scholes pricing model with changes in fair value recorded in the condensed consolidated interim statements of income (loss) and comprehensive income (loss). An input to the model is the risk-free rate which is reflective of US treasury yield rates. Therefore, the Company is exposed to interest rate risk through the non-cash impact it has on the condensed consolidated interim statements of income (loss) and comprehensive income (loss). Additionally, the Company is exposed to interest rate risk from cash and cash equivalents held in interest bearing accounts. The Company maintains its cash balances in highly liquid deposit accounts with reputable financial institutions. These balances are generally held to meet short-term operational and liquidity requirements and are invested in instruments with short maturities to preserve capital and maintain liquidity. As a result, the Company's exposure to fluctuations in interest rates is limited and relates primarily to changes in interest income earned on variable-rate cash deposits. Management monitors prevailing market conditions and interest rates on an ongoing basis. Given the short-term and highly liquid nature of the Company's cash and cash equivalent balances, the fair value of these instruments approximates their carrying value.

 

c.Other price risk

 

Other price risks include the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than interest rate or currency risk). The warrant derivative that is discussed further in Note 14 is recorded at fair value using a Black-Scholes pricing model with changes in fair value recorded in the condensed consolidated interim statements of income (loss) and comprehensive income (loss). An input to the model is the market price of the Company’s shares as of the valuation date. Therefore, the Company is exposed to other price risk through the non-cash impact it has on the condensed consolidated interim statements of income (loss) and comprehensive income (loss).

 

8.Prepaids, deposits, and other current assets

 

   September 30, 2026   December 31, 2025 
   $   $ 
Prepaid insurance   318,533    88,405 
Prepaid membership fees   20,053    43,567 
Prepaid listing fees   30,774    14,512 
Prepaid software   16,003    11,556 
Prepaid licensing fees   23,144    92,576 
Prepaid rent and related deposits   -    37,328 
Clinical study deposits   3,705,736    164,657 
Prepaid manufacturing   24,166    131,710 
Other   15,204    57,338 
    4,153,613    641,649 

 

NERVGEN PHARMA CORP. Q3 2026 INTERIM FINANCIAL STATEMENTS 12 

 

 

NERVGEN PHARMA CORP.

Notes to the condensed consolidated interim financial statements (unaudited)

For the three and nine months ended September 30, 2026 and 2025

(Expressed in Canadian Dollars)

 

9.Receivables

 

   September 30, 2026   December 31, 2025 
   $   $ 
Value added and other taxes receivable   96,970    55,510 
Grants receivable   14,983    25,315 
    111,953    80,825 

 

10.Net investment in lease and lease liability

 

The carrying amounts of the Company’s net investment in lease and lease liabilities and movements during the nine months ended September 30, 2026, were as follows:

 

   Net Investment
in Lease
   Lease Liability 
   $   $ 
Balance December 31, 2025   8,369    8,369 
Lease payments   (8,411)   (8,411)
Lease interest   42    42 
Balance, September 30, 2026   -    - 

 

The Company’s sublease and sub-sublease of the former head office expired on February 26, 2026. The lease arrangement was not renewed and the Company has not entered into a new lease arrangement.

 

11.Intangible asset

 

In June 2018, the Company entered into an exclusive worldwide licensing agreement to research, develop and commercialize a patented technology, with Case Western Reserve University (“CWRU”) in Cleveland, Ohio with potential to bring new therapies for spinal cord injury and other conditions associated with nerve damage.

 

The license costs are being amortized on a straight-line basis over the remaining life of the licensed patent which was 15 years at the time of licensing.

 

Continuity of the intangible asset is as follows:

 

Intangible asset – Case Western Reserve license  Total
$
 
Balance, December 31, 2025   409,163 
Amortization expense   (41,846)
Balance, September 30, 2026   367,317 

 

Under the exclusive worldwide licensing agreement with CWRU to research, develop and commercialize patented technologies, the Company has commitments to pay various annual license fees, patent costs, milestone payments and royalties on revenues, contingent on the achievement of certain development and regulatory milestones. The future milestone payments that are contingent upon the occurrence of future events or future royalties which may be due upon the regulatory approval of products derived from licensed technologies cannot be reasonably estimated. Annual minimum royalty payments are expensed whereas milestone payments related to the cost of the intangible asset are capitalized, as incurred and amortized on a straight-line basis over the remaining life of the patent.

 

As of September 30, 2026, the Company is obligated to pay the following:

 

·An annual minimum royalty of US$50,000 per year, adjusted by the cumulative % change in the Consumer Price Index for Urban Wage Earners and Clerical Workers (“CPI-W”).

 

NERVGEN PHARMA CORP. Q3 2026 INTERIM FINANCIAL STATEMENTS 13 

 

 

NERVGEN PHARMA CORP.

Notes to the condensed consolidated interim financial statements (unaudited)

For the three and nine months ended September 30, 2026 and 2025

(Expressed in Canadian Dollars)

 

11.Intangible asset cont’d

 

·Project milestones payable based on the achievement of future clinical development milestones, up to US$1,885,000, of which US$135,000 has been paid related to milestones achieved. There are up to US$1,750,000 remaining milestone payments as of September 30, 2026.

 

Subsequent to September 30, 2026, a clinical development milestone was achieved triggering a milestone of US$250,000 to be payable.

 

12.Accounts payable and accrued liabilities

 

   September 30, 2026   December 31, 2025 
   $   $ 
Employee related costs   941,598    1,362,925 
Legal and professional fees   652,841    714,529 
Research and development   4,879,495    2,552,529 
Other   202,317    27,465 
    6,676,251    4,657,448 

 

13.Key management personnel

 

Key management personnel, consisting of the Company’s Board of Directors and corporate officers, received the following compensation for the following periods:

 

   Three months ended September 30,   Nine months ended September 30, 
   2026   2025
(Restated – see
Note 4)
   2026   2025
(Restated – see
Note 4)
 
   $   $   $   $ 
Stock-based compensation   958,637    392,597    2,835,703    1,865,408 
Salaries and bonuses   413,863    264,784    752,591    1,728,381 
Consulting   29,398    214,613    236,942    214,613 
    1,401,898    871,994    3,825,236    3,808,402 

 

As of September 30, 2026, the Company had amounts owing or accrued to key management personnel of $236,222 (December 31, 2025 - $332,430) pertaining to accrued bonus, consulting services, and expense reimbursements.

 

Dr. Rogers is a representative of the Company’s largest shareholder PFP Biosciences Holdings LLC (“PFP”) through his role as a Principal and Managing Member of PFP. PFP is considered to have significant influence over the Company by virtue of Dr. Rogers’ role as Chair, President, and CEO, and is therefore considered a related party of the Company. 10,800,000 of the Company’s Common Shares are held by PFP Biosciences Holdings LLC of which 10,000,000 were acquired as part of the July 2022 private placement, and 800,000 were acquired as part of the May 2026 underwritten public offering. Further, associates of PFP, the Paul & Phyllis Fireman Charitable Foundation and the Paul Fireman 2006 Revocable Trust are the beneficial owners of 3,831,530 and 857,143 Common Shares, respectively which were acquired as part of the March 2024 bought deal financing and concurrent private placement and the November 2025 private placement. These entities are also holders of 5,000,000 warrants with an exercise price of $2.44, 1,439,574 warrants with an exercise price of $3.00, 904,761 warrants with an exercise price of US$2.65, and 800,000 warrants with an exercise price of US$3.68 acquired as part of the July 2022, March 2024, November 2025 private placements, and May 2026 public offering, respectively.

 

NERVGEN PHARMA CORP. Q3 2026 INTERIM FINANCIAL STATEMENTS 14 

 

 

NERVGEN PHARMA CORP.

Notes to the condensed consolidated interim financial statements (unaudited)

For the three and nine months ended September 30, 2026 and 2025

(Expressed in Canadian Dollars)

 

14.Warrant derivative

 

On July 13, 2022, pursuant to a non-brokered private placement, 10,150,000 units were sold at a purchase price of US$1.50 per unit for gross proceeds of $19,783,500 (US$15,225,000). Each unit included one Common Share and one-half of one Common Share purchase warrant (the “July ’22 Warrants”). Each whole warrant was exercisable into one Common Share at a price of US$1.75 per Common Share until July 13, 2027. On December 12, 2025, the Company amended the terms of the warrants to change the denomination of the exercise price from US$1.75 to C$2.44. The change in the denomination of the exercise price resulted in the derecognition of the warrant derivative liability and recognition of an equity classified instrument at the fair value as determined on December 12, 2025.

 

On November 19, 2025, pursuant to a non-brokered private placement, 4,785,674 units were sold at a purchase price of US$2.10 per unit for gross proceeds of $14,110,081 (US$10,049,915). Each unit included one Common Share and one-half of one Common Share purchase warrant (the “November ’25 Warrants”). Each whole warrant is exercisable into one Common Share at a price of US$2.65 per Common Share until November 19, 2028.

 

On May 22, 2026, pursuant to an underwritten public offering, 24,000,000 units were sold at a purchase price of US$2.50 per unit for gross proceeds of $82.9 million (US$60.0 million). Each unit included one Common Share and one Common Share purchase warrant (the “May ‘26 Warrants”). Each May ’26 Warrant is exercisable into one Common Share at a price of US$3.68 per Common Share until May 22, 2031.

 

There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised.

 

A reconciliation of the change in fair value of the warrant derivative is as follows:

 

   Fair Value of November ’25
Warrant Derivative
$
   Fair Value of May ‘26
Warrant Derivative
$
   Total Fair Value of
Warrant Derivative
$
 
Balance, December 31, 2025   12,647,514    -    12,647,514 
Recognition of warrant derivative   -    55,921,579    55,921,579 
Exercise of warrants   (54,924)   -    (54,924)
Change in fair value of warrant derivative   (10,051,779)   (23,839,064)   (33,890,843)
Balance, September 30, 2026   2,540,811    32,082,515    34,623,326 

 

The estimated fair value of the warrant derivative was determined using the Black-Scholes valuation model using the following assumptions:

 

November ’25 Warrants  September 30, 2026   December 31, 2025 
Risk-free interest rate   4.88%   2.57%
Expected warrant life in years   1.94    2.62 
Expected stock price volatility   87.49%   82.46%
Dividend yield   -    - 
Warrants outstanding   2,374,332    2,392,832 

 

May ‘26 Warrants  September 30, 2026   December 31, 2025 
Risk-free interest rate   5.09%   - 
Expected warrant life in years   4.65    - 
Expected stock price volatility   75.19%   - 
Dividend yield   -    - 
Warrants outstanding   24,000,000    - 

 

NERVGEN PHARMA CORP. Q3 2026 INTERIM FINANCIAL STATEMENTS 15 

 

 

NERVGEN PHARMA CORP.

Notes to the condensed consolidated interim financial statements (unaudited)

For the three and nine months ended September 30, 2026 and 2025

(Expressed in Canadian Dollars)

 

15.Share capital

 

Authorized

 

Unlimited common shares.

 

Equity Issuances

 

Fiscal 2026

 

During the nine months ended September 30, 2026, 2,623,980 options were exercised for cash proceeds of $4,966,237 and 1,421,020 options were exercised on a cashless basis, for which the Company withheld shares with a fair market value sufficient to satisfy the exercise price, resulting in net 886,011 shares being issued. In addition to the cash proceeds received, the original fair value related to these options of $5,829,408, were transferred from reserves to share capital. Additionally, 357,422 warrants were exercised for cash proceeds of $1,024,101. In addition to the cash proceeds received, the original fair value related to these warrants of $74,101, were transferred from reserves to share capital, and $54,924 was transferred from warrant liability to share capital.

 

The Company also issued and sold 245 Common Shares that were qualified under an at-the-market program (“ATM Program”), pursuant to a prospectus supplement filed on December 19, 2024. These Common Shares were sold at a weighted average price of $6.20 per Common Share for aggregate gross proceeds of $1,519, plus interest from the distribution agent. The Company incurred cash placement fees and professional fees totaling $50,510 related to maintaining and winding down the ATM Program. These costs are recorded as a decrease to Common Shares within the condensed consolidated statements of financial position.

 

On May 22, 2026, the Company closed an underwritten public offering of 24.0 million units at a price of US$2.50 per unit, for aggregate gross proceeds of $82,874,636 (US$60.0 million). Each unit consisted of one Common Share and one Common Share purchase warrant. Each warrant is exercisable into one Common Share at a price of US$3.68 per Common Share until May 22, 2031. The warrants were attributed a value of $55.9 million and the common shares of $27.0 million using the residual value valuation methodology. The value of the warrants was allocated to derivative warrant liability and subsequently remeasured at fair value on September 30, 2026. The Company also paid a cash commission of $4,972,478 to the underwriters, for total net proceeds of $77,902,162. The Company also incurred $826,671 in other share issue costs related to legal, auditor, and listing fees. Share issuance costs of $3,920,232 allocated to the warrant derivative were expensed in the condensed consolidated interim statements of income (loss) and comprehensive income (loss).

 

Fiscal 2025

 

During the nine months ended September 30, 2025, 1,199,503 options were exercised for cash proceeds of $2,250,080. In addition to the cash proceeds received, the original fair value related to these options of $1,554,741, were transferred from reserves to share capital.

 

Additionally, 925,441 warrants were exercised for cash proceeds of $2,758,796. In addition to the cash proceeds received, the original fair value related to these warrants of $269,543, were transferred from reserves to share capital. The Company also issued and sold 949,700 Common Shares under the ATM Program at a weighted average price of $2.92 per share, for aggregate net proceeds of $2,718,742. The Company incurred $629,859 in professional fees related to the establishment of the ATM Program, including $410,255 that were incurred in 2024. These costs are recorded as a decrease to Common Shares within the condensed consolidated statements of financial position.

 

During the nine months ended September 30, 2025, the Company incurred $288,641 in professional fees included in deferred share issuance costs related to ongoing financing activities.

 

NERVGEN PHARMA CORP. Q3 2026 INTERIM FINANCIAL STATEMENTS 16 

 

 

NERVGEN PHARMA CORP.

Notes to the condensed consolidated interim financial statements (unaudited)

For the three and nine months ended September 30, 2026 and 2025

(Expressed in Canadian Dollars)

 

15.Share capital cont’d

 

Calculation of earnings (loss) per share

 

Basic earnings (loss) per common share is calculated using the weighted average number of common shares outstanding.

 

When the Company reports a net loss, potential ordinary shares are generally anti-dilutive and excluded from diluted earnings per share. However, during the period, the Company recognized an unrealized gain on the remeasurement of in-the-money liability-classified warrants, which increased net income (loss) and comprehensive income (loss). As this gain is non-cash and would not arise assuming settlement of the warrants, it is adjusted in the calculation of diluted earnings per share.

 

For diluted earnings per share, the Company assumes settlement of the in-the-money warrants at the beginning of the period, applying the treasury share method. The gain recognized on the warrant liability is reversed in the numerator, and the resulting incremental shares are included in the denominator, where dilutive.

 

Potential ordinary shares are included only when their overall effect is dilutive. The calculation was as follows:

 

   Three Months Ended September 30   Nine Months Ended September 30 
   2026   2025
(Restated – see
Note 4)
   2026   2025
(Restated – see
Note 4)
 
Numerator:                    
Net income (loss) and comprehensive income (loss)                    
Basic   (6,408,493)   (4,718,275)   2,468,896    (17,722,581)
Adjustment for unrealized gain on warrant liability   -    (811,274)   (10,051,779)   - 
Diluted   (6,408,493)   (5,529,549)   (7,582,883)   (17,722,581)
                     
Denominator:                    
Basic   107,455,028    73,162,932    93,528,372    71,937,943 
Adjustment for dilutive effect of liability classified warrants   -    1,572,206    364,352    - 
Diluted   107,455,028    74,735,138    93,892,724    71,937,943 
                     
Basic net income (loss) per share   (0.06)   (0.06)   0.03    (0.25)
Diluted net loss per share   (0.06)   (0.07)   (0.08)   (0.25)
                     

 

NERVGEN PHARMA CORP. Q3 2026 INTERIM FINANCIAL STATEMENTS 17 

 

 

NERVGEN PHARMA CORP.

Notes to the condensed consolidated interim financial statements (unaudited)

For the three and nine months ended September 30, 2026 and 2025

(Expressed in Canadian Dollars)

 

16.Stock options, retention securities, RSUs, PSUs, and warrants

 

Stock-based compensation

 

The following table presents the components of stock-based compensation expense:

 

Stock-based compensation by award type:  Three Months Ended September 30   Nine Months Ended September 30 
   2026   2025
(Restated – see
Note 4)
   2026   2025
(Restated – see
Note 4)
 
Stock options   1,208,719    579,220    3,759,853    3,092,473 
Retention Securities   -    (76,845)   -    (9,203)
Restricted share units   -    -    188,463    - 
Performance share units   61,032    -    400,692    - 
Total   1,269,751    502,375    4,349,008    3,083,270 

 

Stock Options:

 

Stock option transactions for the nine months ended September 30, 2026 are set forth below:

 

   Number of shares
issuable under
options
   Weighted average
exercise price
$
 
Balance outstanding at December 31, 2025   9,275,900    2.31 
Granted   3,809,527    5.24 
Exercised   (4,045,000)   1.88 
Forfeited/Expired   (580,900)   2.53 
Balance outstanding at September 30, 2026   8,459,527    3.78 

 

Stock options granted during the period vest subject to continued service to the company and/or achievement of certain predefined company-specific performance-based criteria.

 

The following table summarizes information about stock options outstanding at September 30, 2026:

 

Exercise
Price ($)
  Number of
Options
Outstanding
   Weighted
average
remaining
contractual
life (Years)
   Weighted
average
exercise
Price ($)
   Number of
Options
Exercisable
   Weighted
average
remaining
contractual
life (Years)
   Weighted
average
exercise
Price ($)
 
1.01-1.50   38,000    3.52    1.13    38,000    3.52    1.13 
1.51-2.00   1,940,000    2.13    1.79    1,940,000    2.13    1.79 
2.01-2.50   360,000    2.62    2.18    360,000    2.62    2.18 
2.51-3.00   936,532    7.98    2.89    484,750    6.39    2.85 
3.01-3.50   1,279,000    5.66    3.18    894,000    3.82    3.17 
3.51-4.00   867,500    3.64    3.81    824,583    3.62    3.82 
5.01-5.50   2,133,110    9.60    5.41    15,630    9.49    5.32 
5.51-6.00   187,494    9.43    5.70    11,719    9.43    5.69 
6.51-7.00   614,799    9.37    6.87    -    -    - 
7.51-8.00   103,092    4.36    7.56    -    -    - 
    8,459,527    6.09    3.78    4,568,682    3.27    2.58 

 

NERVGEN PHARMA CORP. Q3 2026 INTERIM FINANCIAL STATEMENTS 18 

 

 

NERVGEN PHARMA CORP.

Notes to the condensed consolidated interim financial statements (unaudited)

For the three and nine months ended September 30, 2026 and 2025

(Expressed in Canadian Dollars)

 

16.Stock options, retention securities, RSUs, PSUs, and warrants cont’d

 

The fair value of options granted is calculated on the grant date using the Black-Scholes option pricing model using the following assumptions:

 

    September 30, 2026    September 30, 2025
(Restated – see Note 4)
 
 
Risk-free interest rate   3.75% - 4.83%    2.72% - 3.19% 
Expected term in years   4.8 – 9.5 years    4.0 – 9.2 years 
Expected stock price volatility   72.4% - 75.56%    65.7% - 73.7% 
Dividend yield   -    - 

 

Retention Securities:

 

The Company granted 590,000 retention securities to its former President and Chief Executive Officer in connection with his appointment on April 10, 2023. As a result of the resignation of the former President and Chief Executive Officer in July 2025, 98,333 retention securities were forfeited. The remaining 491,667 retention securities expired unexercised on July 16, 2026.

 

The retention securities were granted outside of the Company’s stock option plan, as an inducement grant to the former President and Chief Executive Officer of the Company pursuant to Section 6.4 of TSX Venture Exchange Policy 4.4.

 

Restricted Stock Units (RSUs):

 

The Company granted RSUs to the CEO which vested immediately upon the date of grant. Each RSU entitled the holder to receive one common share of the Company upon vesting. Stock-based compensation expense is recognized over the period in which the RSUs vested.

 

RSU transactions for the nine months ended September 30, 2026 are set forth below:

 

   Number of shares
issuable under RSU
 
Balance outstanding at December 31, 2025   - 
Granted   37,784 
Vested   (37,784)
Forfeited/Expired   - 
Balance outstanding at September 30, 2026   - 

 

The weighted-average grant-date fair value of RSUs granted during the nine months ended September 30, 2026 was $4.99 per unit. The Company recognized stock-based compensation expense of $188,463 during the nine months ended September 30, 2026 related to RSU awards.

 

Performance Stock Units (PSUs):

 

The Company grants PSUs to members of senior management. Vesting is subject to the achievement of certain predefined company-specific performance-based criteria within the 2026 calendar year, subject to continued employment at each performance objective achievement date. Each PSU entitles the holder to receive one common share of the Company upon vesting. Stock-based compensation expense is recognized over the vesting period based on management's best estimate of the number of awards expected to vest. These estimates are reassessed at each reporting date.

 

NERVGEN PHARMA CORP. Q3 2026 INTERIM FINANCIAL STATEMENTS 19 

 

 

NERVGEN PHARMA CORP.

Notes to the condensed consolidated interim financial statements (unaudited)

For the three and nine months ended September 30, 2026 and 2025

(Expressed in Canadian Dollars)

 

16.Stock options, retention securities, RSUs, PSUs, and warrants cont’d

 

PSU transactions for the nine months ended September 30, 2026 are set forth below:

 

   Number of shares
issuable under PSU
 
Balance outstanding at December 31, 2025   - 
Granted   617,135 
Vested   (61,713)
Forfeited/Expired   (246,854)
Balance outstanding at September 30, 2026   308,568 

 

The weighted-average grant-date fair value of PSUs granted during the nine months ended September 30, 2026 was $4.99 per unit. The Company recognized stock-based compensation expense of $400,692 during the year related to PSU awards and had $1,446,229 of unrecognized expense related to unvested PSUs as of September 30, 2026.

 

Warrants:

 

Warrant transactions for the nine months ended September 30, 2026 are set forth below:

 

   Number of shares
issuable under
warrants
   Weighted average
exercise price
US$
   Weighted average
exercise price
$
 
Balance outstanding at December 31, 2025   11,339,848    2.65    2.88 
Granted   24,000,000    3.68    5.22 
Exercised   (357,422)        2.87 
Balance outstanding at September 30, 2026   34,982,426         4.49 

 

The following table summarizes information about warrants outstanding at September 30, 2026:

 

Exercise Price ($)  Number of Warrants Outstanding   Grant Date  Expiry Date
2.44   5,075,000   July 13, 2022  July 13, 2027
3.00   3,533,094   March 28, 2024  March 28, 2027
3.76 (US 2.65)   2,374,332   November 19, 2025  November 19, 2028
5.22 (US 3.68)   24,000,000   May 22, 2026  May 22, 2031
    34,982,426       

 

17.Commitments

 

In the normal course of business, the Company enters into contracts for the procurement of research and related services. These contracts are typically cancellable by the Company with notice.

 

In June 2023, the Company was awarded a grant of up to US$3.18 million (CA$4.22 million) to support the Company’s Phase 1b/2a clinical trial in individuals with SCI. In connection with the grant, the Company agreed to pay a percentage of the Company’s net annual sales revenue of NVG-291 or any derivative approved in SCI through the provision of an unrestricted donation to the granting entity in the amount of up to the total funds received through the agreement. Any donation that may become due under the agreement is dependent on, among other factors, the successful development and sale of a new drug, the outcome and timing of which is uncertain. As of September 30, 2026, the grant had concluded and the Company had received US$2.56 million (CA$3.40 million) over the life of the grant. There are no future proceeds expected to be received under this grant. The grant funding received was recorded as a reduction of the related clinical and regulatory expenses, included in research and development expenses, in the period the milestone was earned.

 

NERVGEN PHARMA CORP. Q3 2026 INTERIM FINANCIAL STATEMENTS 20 

 

 

NERVGEN PHARMA CORP.

Notes to the condensed consolidated interim financial statements (unaudited)

For the three and nine months ended September 30, 2026 and 2025

(Expressed in Canadian Dollars)

 

18.Nature of expenses

 

   Three Months Ended
September 30
   Nine Months Ended
September 30
 
   2026   2025
(Restated – see
Note 4)
   2026   2025
(Restated – see
Note 4)
 
   $   $   $   $ 
Research and Development Expenses                    
Amortization of intangible asset   13,949    13,949    41,846    41,846 
Preclinical development   889,726    102,887    2,067,959    649,013 
Chemistry, manufacturing and controls   1,603,031    1,229,660    5,887,347    1,927,563 
Licensing and patent legal fees   99,955    210,947    312,988    335,106 
Clinical and regulatory   3,790,370    1,037,342    8,812,673    2,115,971 
Salaries and benefits   1,207,564    1,103,311    2,309,708    3,455,672 
Stock-based compensation   135,555    408,432    635,161    1,035,202 
Other research and development   159,986    158,038    408,446    373,976 
    7,900,136    4,264,566    20,476,128    9,934,349 

 

   Three Months Ended
September 30
   Nine Months Ended
September 30
 
   2026   2025
(Restated – see
Note 4)
   2026   2025
(Restated – see
Note 4)
 
   $   $   $   $ 
General and Administrative Expenses                
Legal, professional and finance  606,950   269,979   1,662,192   1,040,095 
Investor and public relations   284,525    249,842    1,265,863    1,157,841 
Salaries and benefits   747,891    574,341    1,608,941    2,470,803 
Stock-based compensation   1,134,196    93,942    3,713,847    2,048,068 
Other general and administrative   514,188    108,042    1,579,650    514,704 
    3,287,750    1,296,146    9,830,493    7,231,511 

 

19.Subsequent events

 

Subsequent to September 30, 2026, the Company:

 

(a)achieved a clinical development milestone upon the dosing of the first participant in RESTORE, the Company’s Phase 3 registrational trial evaluating NVG-291 in chronic tetraplegia, triggering a milestone payment to CWRU of US$250,000.

 

NERVGEN PHARMA CORP. Q3 2026 INTERIM FINANCIAL STATEMENTS 21 

 

 

Exhibit 99.2

 

 

Management’s Discussion and Analysis of

 

NERVGEN PHARMA CORP.

(Expressed in Canadian Dollars)

 

For the three and nine months ended September 30, 2026 and 2025

 

Effective Date: November 16, 2026

 

 

 

 

MANAGEMENT’S DISCUSSION AND ANALYSIS

 

The following discussion is management’s assessment and analysis of the results of operations and financial condition of NervGen Pharma Corp. (the “Company” or “NervGen”) and should be read in conjunction with the accompanying condensed consolidated interim financial statements and related notes thereto for the period ended September 30, 2026.

 

All financial information in this Management’s Discussion and Analysis (“MD&A”) has been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and all dollar amounts are expressed in Canadian dollars unless otherwise indicated.

 

FORWARD-LOOKING STATEMENTS

 

This MD&A contains “forward-looking statements” within the meaning of U.S. securities laws and “forward-looking information” within the meaning of applicable Canadian securities legislation (collectively, the “forward-looking statements”). Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenue or performance, capital expenditures, financing and other information that is not historical information. These statements appear in a number of different places in this MD&A and can often be identified by words such as “anticipates”, “estimates”, “projects”, “expects”, “intends”, “believes”, “plans”, “will”, “could”, “may”, or their negatives or other comparable words. Such forward-looking statements are necessarily based on estimates and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements.

 

Forward-looking statements in this MD&A, include, but are not limited to, statements relating to:

 

·our expectations regarding the sufficiency of our capital resources and requirements for additional capital;
·requirements for, and the ability to obtain, future funding on favorable terms or at all, and the intended use of proceeds from financings;
·business strategy;
·expected future loss and accumulated deficit levels;
·projected financial position and estimated cash expenditure rate;
·expectations about the timing of achieving milestones and the cost of our development programs;
·estimates of the size and characteristics of the potential markets for our product candidates;
·observations and expectations regarding the efficacy and durability of drug candidates, NVG-291 and NVG-300, and the potential benefits to patients;
·our ability to successfully develop NVG-291 and NVG-300;
·the term of NVG-291’s and NVG-300’s intellectual property protection;
·plans to use and evaluate NVG-291 and other potential drug candidates in our clinical development programs;
·plans to develop additional proprietary compounds that address nervous system repair;
·expectations and intended benefits of memorandums of understanding and agreements entered into with third parties;
·expectations about the timing with respect to commencement and completion of clinical trials;
·expectations about the timing and future plans with respect to preclinical and clinical studies;
·expectations regarding the objectives, endpoints and evaluation criteria of our ongoing clinical trials;
·expectations relating to the removal of the partial clinical trial hold initiated by the U.S. Food and Drug Administration (“FDA”);
·expectations regarding interactions with the FDA regarding future clinical development of our product candidates, including potential accelerated approval;
·expected results of toxicology studies with respect to NVG-291 and other potential drug candidates;
·expectations about our product candidates’ safety and efficacy;
·our ability to identify and secure sources of funding for the development of our product candidates and technologies;
·expectations regarding our ability to arrange for the manufacturing of our product candidates and technologies;
·expectations regarding the cost, progress and successful and timely completion of the various stages of the regulatory approval process;
·expectations about the potential benefits of Fast Track designation for NVG-291 in the treatment of spinal cord injury (“SCI”);
·ability to secure strategic partnerships with larger pharmaceutical and biotechnology companies;
·strategy to acquire and develop new product candidates and technologies and to enhance the safety and efficacy of existing products and technologies;

 

NERVGEN PHARMA CORP. 2026 Q3 MD&A1 

 

 

·plans to market, sell and distribute our products and technologies, if approved;
·expectations regarding the acceptance of our products and technologies by the market, if approved;
·expectations regarding the commercial opportunities of our products and technologies;
·expectations regarding the use of our products and technologies in treating diseases and medical disorders;
·ability to retain and access appropriate staff, management, and expert advisers;
·expectations with respect to existing and future contractual obligations, corporate alliances, and licensing transactions with third parties, and the receipt and timing of any payments to be made by us or to us in respect of such arrangements;
·our plans for remediating the material weakness in our internal controls that was previously identified by our management; and
·strategy and ability with respect to the protection of our intellectual property.

 

Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements.

 

In making the forward-looking statements included in this MD&A, we have made various material assumptions, including but not limited to:

 

·our ability to obtain financing on acceptable terms;
·additional sources of funding, including grants and funding from partners;
·our ability to attract and retain skilled staff;
·favorable general business and economic conditions;
·pandemics not having a material impact on our operations;
·our future research and development plans proceeding substantially as currently envisioned;
·our ability to obtain positive results from our research and development activities, including clinical trials;
·future expenditures to be incurred by us;
·research and development and operating costs;
·our ability to find partners in the pharmaceutical industry;
·the products and technology offered by our competitors;
·the impact of competition on our operations;
·our ability to identify additional product candidates;
·our ability to obtain regulatory and other approvals to commence additional clinical trials involving current and future product candidates;
·our ability to successfully out-license or sell our future products, if any, and in-license and develop new products;
·our ability to protect patents and proprietary rights; and
·expected research and development tax credits.

 

In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors, including the risks outlined herein under the headings “Credit risk”, “Liquidity risk”, “Foreign currency risk”, “Market risk” and “Other price risk”, and under the heading “Risk Factors” in our most recently filed Annual Information Form (the “AIF”), our amended and restated short form base shelf prospectus dated December 15, 2025, as amended on May 22, 2026, available under our profile on SEDAR+ at www.sedarplus.ca, and incorporated by reference in our Form F-10 filed with the Securities and Exchange Commission (the “SEC”) on May 26, 2026 and included in our Annual Report on Form 40-F/A filed with the SEC on October 16, 2026 and available under our profile on SEC.gov. Certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties related to the fact that:

 

·we have a limited operating history, are early in our development efforts, and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability;
·since our inception, we have incurred significant net losses and expect to continue to incur significant net losses for the foreseeable future and we may never achieve or maintain profitability;
·we will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and development programs or future commercialization efforts;

 

NERVGEN PHARMA CORP. 2026 Q3 MD&A2 

 

 

·positive results from early preclinical studies and clinical trials of our current or future product candidates are not necessarily predictive of the results of later preclinical studies and clinical trials of our current or future product candidates. If we cannot replicate the positive results from our preclinical studies or early clinical trials of our current or future product candidates, we may be unable to successfully raise sufficient financing to develop, obtain regulatory approval for and commercialize our current or future product candidates;
·we have a history of negative operating cash flow and may continue to experience negative operating cash flow;
·raising additional capital may cause dilution to our shareholders, restrict our operations or require us to relinquish rights to our technologies or product candidates;
·our ability to utilize our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be limited;
·we are substantially dependent on the success of our lead product candidate, NVG-291, which we are evaluating in a Phase 3 clinical trial for chronic tetraplegia. If we are unable to complete development of, obtain approval for and commercialize NVG-291 for SCI in a timely manner, our business will be harmed;
·there are currently no FDA-approved products for the treatment of SCI;
·the regulatory approval processes of the FDA, European Medicines Agency (“EMA”), Health Canada and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to commercialize our product candidates and generate product revenue and our business will be substantially harmed;
·preclinical studies and clinical trials are expensive, time-consuming, difficult to design and implement and involve an uncertain outcome. Further, we may encounter substantial delays in completing the development of our product candidates;
·our current or future product candidates may cause significant adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could delay or prevent regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences. NVG-291 for SCI is currently subject to a partial clinical hold by the FDA, and we may be unable to have the hold removed which could adversely affect development of NVG-291 and our results of operations;
·the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA, Health Canada or other comparable foreign regulatory authorities;
·interim, ”top-line”, and preliminary data from our clinical trials that we announce or publish from time to time may change as more participant data becomes available and are subject to audit and verification procedures that could result in material changes in the final data;
·if we fail to develop and commercialize NVG-291 for additional indications or fail to discover, develop and commercialize other product candidates, we may be unable to grow our business and our ability to achieve our strategic objectives would be impaired;
·we may expend our limited resources to pursue a particular product or indication and fail to capitalize on products or indications that may be more profitable or for which there is a greater likelihood of success;
·changes in methods of product candidate manufacturing or formulation may result in additional costs or delay;
·if we are unable to successfully develop companion diagnostics or biomarkers that may be required for our therapeutic product candidates, or experience significant delays in doing so, we may not achieve marketing approval or realize the full commercial potential of our therapeutic product candidates;
·if we experience delays or difficulties in the enrollment and/or retention of participants in clinical trials, our clinical development activities could be delayed or otherwise adversely affected;
·as an organization, we have never conducted later-stage clinical trials or submitted a new drug application, and may be unable to do so for any of our product candidates;
·we face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer, or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted;
·Fast Track or Breakthrough Therapy designation by the FDA may not actually lead to a faster development or regulatory review or approval process, and does not assure FDA approval of our product candidates;
·we may seek orphan drug designation for the product candidates we develop, and we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity;
·even if approved, our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success;
·if the market opportunity for any product candidate that we develop is smaller than we believe, our revenue may be adversely affected and our business may suffer;

 

NERVGEN PHARMA CORP. 2026 Q3 MD&A3 

 

 

·if we are unable to establish sales, marketing and distribution capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be successful in commercializing our product candidates that obtain regulatory approval;
·our use of third parties to manufacture our product candidates may increase the risk that we will not have sufficient quantities of our product candidates, products, or necessary quantities of such materials on time or at an acceptable cost;
·we rely on third parties to assist in conducting our clinical trials. If they do not perform satisfactorily, we may not be able to obtain regulatory approval or commercialize our product candidates, or such approval or commercialization may be delayed, and our business could be substantially harmed;
·we may seek to establish collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans;
·if we enter into collaborations with third parties for the development and commercialization of our product candidates, our prospects with respect to those product candidates will depend in significant part on the success of those collaborations;
·we may be subject to claims that we or our employees, independent contractors, or consultants have wrongfully used or disclosed alleged confidential information or trade secrets;
·even if our product candidates receive regulatory approval, they will be subject to significant post marketing regulatory requirements and oversight;
·obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions;
·any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations;
·we may face difficulties from changes to current regulations and future legislation. Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations;
·our relationships with healthcare professionals, clinical investigators, clinical research organizations (“CROs”), and third party payors in connection with our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished profits and future earnings;
·failure to comply with laws, rules, regulations, policies, industry standards and contractual obligations relating to privacy, data protection and data security could adversely affect our business;
·if we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business;
·disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business;
·we are subject to certain U.S. and non-U.S. anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations;
·if we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our future licensors, we could lose license rights that are important to our business;
·our success depends on our ability to protect our intellectual property and our proprietary technologies;
·if the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected;
·intellectual property rights do not necessarily address all potential threats to our competitive advantage;
·patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time;
·others may challenge inventorship or claim an ownership interest in our intellectual property which could expose it to litigation and have a significant adverse effect on its prospects;
·if we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates;

 

NERVGEN PHARMA CORP. 2026 Q3 MD&A4 

 

 

·we may be involved in lawsuits to protect or enforce our patents or our future licensors’ patents, which could be expensive, time consuming, and unsuccessful. Further, our issued patents or our future licensors’ patents could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad;
·we may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products and product candidates;
·changes in U.S. patent law, or laws in other countries, or their interpretation could diminish the value of patents in general, thereby impairing our ability to protect our product candidates;
·we may not be able to protect or enforce our intellectual property rights throughout the world;
·if our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected;
·if we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected, harming our business and competitive position;
·our rights to develop and commercialize our technology and product candidates may be subject, in part, to the terms and conditions of any future licenses granted to us by others;
·the patent protection and patent prosecution for some of our product candidates may be dependent on third parties;
·we depend heavily on our executive officers, principal consultants and others, and the loss of their services would materially harm our business;
·we only have a limited number of employees to manage and operate our business;
·our future growth may depend, in part, on our ability to operate internationally, where we would be subject to additional regulatory burdens and other risks and uncertainties;
·we expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations;
·the market price of our common shares (the “Common Shares”) may be volatile, and you could lose all or part of your investment;
·sales of a substantial number of shares of our Common Shares in the public market could cause our share price to fall;
·if remediation of the material weakness previously identified by our management, which resulted in the restatement of certain of our previously issued financial statements, is not effective, or if we fail to maintain an effective system of internal control over financial reporting in the future, we may not be able to accurately or timely report our financial condition or operating results, which may adversely affect investor confidence in our company and, as a result, the value of our Common Shares;
·the restatement of certain previously issued financial statements may affect investor confidence and raise reputational issues and may subject us to additional risks and uncertainties, including increased professional costs and the increased possibility of legal proceedings and regulatory inquiries;
·we do not know whether a market for our Common Shares will develop to provide you with adequate liquidity;
·we do not intend to pay dividends on our Common Shares in the foreseeable future, so any returns will be limited to the value of our Common Shares;
·if securities or industry analysts either do not publish research about us or publish inaccurate or unfavorable research about us, our business or our market, or if they adversely change their recommendations regarding our Common Shares, the trading price or trading volume of our Common Shares could decline;
·we have broad discretion in the use of the net proceeds from any offering and may not use them effectively;
·investing in our securities is speculative, and investors could lose their entire investment;
·our constating documents permit us to issue an unlimited number of Common Shares without additional shareholder approval which could result in dilution;
·the exercise of stock options and warrants could cause dilution;
·it is possible that our status with regards to whether we are a “passive foreign investment company” may change, which could have adverse U.S. federal income tax consequences for U.S. shareholders;
·it may be difficult for non-Canadian investors to obtain and enforce judgments against us because of our Canadian incorporation and presence;
·we are subject to the informational requirements of the Exchange Act; however, as a foreign private issuer, we are subject to different U.S. securities laws and requirements than a domestic U.S. issuer, which reduces the information we are required to provide to our U.S. shareholders;
·we expect to lose our foreign private issuer status in 2027, which will likely result in significant additional costs and expenses;

 

NERVGEN PHARMA CORP. 2026 Q3 MD&A5 

 

 

·we have devoted, and will continue to devote significant resources to regulatory compliance as a public entity. These resource requirements will increase now that our Common Shares are listed on the Nasdaq Stock Market LLC;
·our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage such inability could have an adverse effect on our business and financial condition;
·cyber-attacks or other failures in our telecommunications or information technology systems, or those of our collaborators, CROs, third-party logistics providers, distributors or other contractors or consultants, could result in information theft, data corruption and significant disruption of our business operations; and
·we may be subject to securities litigation, which is expensive and could divert management attention.

 

If one or more of these risks or uncertainties or a risk that is not currently known to us materialize, or if our underlying assumptions prove to be incorrect, actual results may vary significantly from those expressed or implied by forward-looking statements. The forward-looking statements represent our views as of the date of this MD&A. While we may elect to update these forward-looking statements in the future, we have no current intention to do so except as to the extent required by applicable securities law. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements. We advise you that these cautionary remarks expressly qualify in their entirety all forward-looking statements attributable to us or persons acting on our behalf.

 

COMPANY OVERVIEW

 

NervGen Pharma Corp. was incorporated on January 19, 2017. The Company’s Principal Executive Office is 1200 Brickell Avenue, Suite 1950 #IP 1346 Miami, FL 33131.

 

NervGen is a publicly traded (NASDAQ: NGEN), clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for SCI and other traumatic and neurologic disorders. Our principal business activity is the discovery, development and commercialization of pharmaceutical products that may enable the nervous system to repair itself, with our initial focus on SCI. We are also utilizing our intellectual property and know- how to develop our products for other related medical conditions.

 

We are evaluating the efficacy of our lead molecule, NVG-291, in a Phase 3 clinical trial in chronic tetraplegia. We hold the exclusive worldwide rights to both NVG-291 and NVG-300. NVG-291’s technology is licensed from Case Western Reserve University (“CWRU”) and is based on academic studies demonstrating the preclinical efficacy of NVG-291-R, the rodent variant of NVG-291, in animal models of spinal cord injury. NVG-291 has been granted Fast Track designation by the FDA and Orphan Drug Designation from the EMA. We may also seek FDA Orphan Drug Designation and/or Breakthrough Therapy Designation, where appropriate, should our research indicate that such applications may assist in the development of our drug candidates.

 

We currently have no commercial products or services and do not generate operating revenues. The development of pharmaceutical products and the receipt of the necessary regulatory approvals required for commercialization typically involve lengthy and uncertain processes. As a result, no near-term revenues from product sales or services are expected.

 

These objectives replace and supersede those described in the “Description and General Development of the Business of the Company” section of our amended and restated short form base shelf prospectus dated December 15, 2025 and amended on May 22, 2026 (the “Base Shelf”). All clinical development plans are subject to our ability to obtain additional funding (see “Liquidity and Capital Resources” below).

 

ACHIEVEMENTS & HIGHLIGHTS

 

The following are the achievements and highlights for the nine months ended September 30, 2026, through to the date hereof:

 

·On January 8, 2026, we announced that our Common Shares had been approved for listing on Nasdaq and began trading on the exchange under the symbol “NGEN.”

 

·On February 9, 2026, we announced the appointment of Adam Rogers, MD, as President and Chief Executive Officer (“CEO”). Adam Rogers was previously serving as the Company’s interim CEO and remains the Chairman of the Company’s Board of Directors.

 

NERVGEN PHARMA CORP. 2026 Q3 MD&A6 

 

 

·On February 12, 2026, we announced the retirement of Bill Adams, Chief Financial Officer, effective March 15, 2026. On February 13, 2026, we announced Adam Rogers will serve as the Company’s interim Chief Financial Officer and the Company’s Principal Financial and Accounting Officer, beginning on March 15, 2026.

 

·On March 12, 2026, we announced that we would voluntarily delist our Common Shares from the TSX Venture Exchange effective March 16, 2026. Concurrently with the announcement we terminated our at-the-market program (the “ATM Program”) effective March 12, 2026.

 

·On April 7, 2026, we announced the completion of a successful End-of-Phase 2 meeting with the FDA reaching alignment on RESTORE, our Phase 3 registrational study designed to evaluate NVG-291 for the treatment of chronic tetraplegia. Additionally, we announced our decision to conclude enrollment in our Phase 1b/2a CONNECT SCI study in subacute tetraplegia and unblind available data.

 

·On April 27, 2026, we announced the appointment of Keith Vendola, MD, MBA, as our Chief Financial Officer.

 

·On May 22, 2026, we closed a US$60.0 million underwritten public offering of 24,000,000 Common Shares and accompanying warrants to purchase up to 24,000,000 Common Shares.

 

·On May 26, 2026, we announced positive independent, blinded biomechanical gait post-hoc analyses demonstrating genuine neural recovery with NVG-291 in the Phase 1b/2a CONNECT SCI study.

 

·On October 12, 2026, we announced the first participant dosed in RESTORE, our Phase 3 registrational study evaluating NVG-291 in chronic tetraplegia.

 

SELECTED FINANCIAL INFORMATION

 

   Three Months Ended September 30   Nine Months Ended September 30 
   2026   2025   2026   2025 
       (Restated)       (Restated) 
   $   $   $   $ 
Research and development expenses   7,900,136    4,264,566    20,476,128    9,934,349 
General and administrative expenses   3,287,750    1,296,146    9,830,493    7,231,511 
Net income (loss)   (6,408,493)   (4,718,275)   2,468,896    (17,722,581)
Basic income (loss) per share   (0.06)   (0.06)   0.03    (0.25)
Diluted income (loss) per share   (0.06)   (0.07)   (0.08)   (0.25)

 

   September 30, 2026   December 31, 2025   September 30, 2025 
   $   $   $ 
Total assets   85,076,071    23,209,641    13,077,452 
Total liabilities   41,299,577    17,313,331    14,349,607 

 

As of the date of this MD&A, we have not earned revenue other than income from interest earned on our cash and cash equivalents.

 

The increase in net loss for the three months ended September 30, 2026, compared to the same period in the prior year is primarily driven by higher research and development and general and administrative expenses, partially offset by a greater non-cash gain on the fair value of the warrant derivatives related to U.S. dollar denominated warrants and higher interest income. Further, when compared to the prior three-month period, the current period reflects an increase in research and development related expense, primarily related to costs associated with initiating our Phase 3 clinical trial evaluating NVG-291 in chronic tetraplegia. General and administrative related expenses, also increased for the three months ended September 30, 2026 compared to the same period in 2025, primarily driven by costs incurred to attract and retain personnel resources to support our growth and advancement, including fees to recruitment agencies and non-cash stock-based compensation expense.

 

NERVGEN PHARMA CORP. 2026 Q3 MD&A7 

 

 

The net income for the nine months ended September 30, 2026, compared to a net loss for the same period in the prior year, is primarily driven by a non-cash gain on the fair value of the warrant derivatives related to U.S. dollar denominated warrants, partially offset by higher research and development and general and administrative expenses and finance costs of $3,920,232 related to share issuance costs allocated to the warrant derivative. Further, when compared to the prior nine month period, the current period reflects an increase in research and development related expense, primarily related to costs associated with initiating our Phase 3 clinical trial evaluating NVG-291 in chronic tetraplegia, manufacturing activities to support clinical and non-clinical activities, as well as other activities such as non-clinical toxicology studies for NVG-291. General and administrative related expenses, also increased for the nine months ended September 30, 2026 compared to the same period in 2025, primarily driven by costs incurred to attract and retain personnel resources to support our growth and advancement, including fees to recruitment agencies and non-cash stock-based compensation expense. Additionally, the increase in general and administrative related expenses was driven by professional and other administrative costs associated with our Nasdaq listing and other corporate securities matters.

 

The increase in our total assets at September 30, 2026 compared to September 30, 2025 and December 31, 2025, is mainly due to an increase in cash, which is attributable to proceeds from the May 2026 underwritten public offering. The increase in our total liabilities at September 30, 2026 as compared to September 30, 2025 and December 31, 2025 is primarily attributable to the recognition of a non-cash warrant derivative associated with the warrants sold in the May 2026 underwritten public offering.

 

RESULTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026

Research and Development Expenses

 

   Three Months Ended September 30   Nine Months Ended September 30 
   2026   2025   2026   2025 
       (Restated)       (Restated) 
   $   $   $   $ 
Amortization of intangible asset   13,949    13,949    41,846    41,846 
Preclinical development   889,726    102,887    2,067,959    649,013 
Chemistry, manufacturing and controls   1,603,031    1,229,660    5,887,347    1,927,563 
Licensing and patent legal fees   99,955    210,947    312,988    335,106 
Clinical and regulatory   3,790,370    1,037,342    8,812,673    2,115,971 
Salaries and benefits   1,207,564    1,103,311    2,309,708    3,455,672 
Stock-based compensation   135,555    408,432    635,161    1,035,202 
Other research and development   159,986    158,038    408,446    373,976 
    7,900,136    4,264,566    20,476,128    9,934,349 

 

The increase of $3,635,570 in research and development expenses in the three months ended September 30, 2026, as compared to the three months ended September 30, 2025, is primarily attributable to the following factors:

 

·Preclinical development expense increased by $786,839. The current period includes greater expenses related to non-clinical studies for NVG-291, such as embryofetal and chronic toxicology studies.
·Chemistry, manufacturing and controls (“CMC”) expense increased by $373,371, primarily driven by manufacturing of drug substance and drug product to supply our ongoing Phase 3 clinical trial evaluating NVG-291 in chronic tetraplegia, as well as ongoing non-clinical toxicology studies.
·Licensing and patent legal fees decreased by $110,992 due to the timing of patent maintenance, filing costs, and licensing fees.
·Clinical and regulatory costs increased by $2,753,028 primarily driven by fees paid to CROs and consultants who supported the initiation of our Phase 3 clinical trial evaluating NVG-291 in chronic tetraplegia. These increases were partially offset by a decrease in costs associated with our Phase 1b/2a trial given the trial concluded during the first half of 2026.
·Salaries and benefits increased by $104,253 primarily due to the realignment of our personnel resources to better support NVG-291 at its current phase of development.
·Non-cash stock-based compensation expense decreased by $272,877, primarily driven by recent awards issued with longer vesting periods compared to awards vesting during the comparative period.

 

NERVGEN PHARMA CORP. 2026 Q3 MD&A8 

 

 

The increase of $10,541,779 in research and development expenses in the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025, is primarily attributable to the following factors:

 

·Preclinical development expense increased by $1,418,946. The current period includes greater expenses related to non-clinical studies for NVG-291, such as embryofetal and chronic toxicology studies.
·CMC expense increased by $3,959,784, primarily driven by manufacturing of drug substance and drug product to supply our ongoing Phase 3 clinical trial evaluating NVG-291 in chronic tetraplegia and non-clinical toxicology studies.
·Licensing and patent legal fees decreased by $22,118 due to the timing of patent maintenance, filing costs, and licensing fees.
·Clinical and regulatory costs increased by $6,696,702 primarily driven by fees incurred to CROs and consultants who supported the initiation of our Phase 3 clinical trial evaluating NVG-291 in chronic tetraplegia. These increases were partially offset by a decrease in costs associated with our Phase 1b/2a trial given the trial concluded during the first half of 2026.
·Salaries and benefits decreased by $1,145,964 primarily due to turnover in research and development leadership in the prior year, including our Chief Medical Officer, as we purposefully strengthened our research and development personnel throughout 2026, realigning our personnel resources to better support NVG-291 at its current phase of development.
·Non-cash stock-based compensation expense decreased by $400,041, primarily driven by recent awards issued with longer vesting periods compared to awards vesting during the comparative period.

 

General and Administrative Expenses

 

   Three Months Ended September 30   Nine Months Ended September 30 
   2026   2025   2026   2025 
       (Restated)       (Restated) 
   $   $   $   $ 
Legal, professional and finance   606,950    269,979    1,662,192    1,040,095 
Investor and public relations   284,525    249,842    1,265,863    1,157,841 
Salaries and benefits   747,891    574,341    1,608,941    2,470,803 
Stock-based compensation   1,134,196    93,942    3,713,847    2,048,068 
Other general and administrative   514,188    108,042    1,579,650    514,704 
    3,287,750    1,296,146    9,830,493    7,231,511 

 

The increase of $1,991,604 in general and administrative expenses in the three months ended September 30, 2026, as compared to the three months ended September 30, 2025, is primarily attributable to the following factors:

 

·Legal, professional, and financial services expenses increased by $336,971 during the three-month period, primarily due to higher audit fees following our change of auditor to a US-based auditor. Further, we incurred higher legal fees associated with various corporate development initiatives, partially offset by a decrease in consulting fees due to realignment of our external resources to better support NVG-291 at its current phase of development.
·Investor and public relations expenses increased by $34,683 during the three-month period. This increase reflects an increase in public relations efforts and press release visibility, as well as an increase in filing fees following our listing on Nasdaq.
·Employee salaries, bonuses, and benefits increased by $173,550 during the three-month period, primarily due to lower employee compensation expense for our CEO position in the prior period following the termination of our former CEO in July 2025, during which the severance paid to our former CEO was largely offset by the reversal of a corresponding accrued bonus.
·Non-cash stock-based compensation expense increased by $1,040,254 for the three-month period, primarily driven by option awards forfeited in the prior period upon termination of employment and services for several individuals within the general and administrative function, including our former CEO and former Chair of our board of directors.
·Other general and administrative expenses increased by $406,146 primarily due to an increase in Director and Officer insurance premiums as a result of our listing on Nasdaq, as well as an increase in employee recruitment efforts in the current period.

 

NERVGEN PHARMA CORP. 2026 Q3 MD&A9 

 

 

The increase of $2,598,982 in general and administrative expenses in the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025, is primarily attributable to the following factors:

 

·Legal, professional, and financial services expenses increased by $622,097 primarily due to higher fees paid to external legal counsel in connection with various corporate development initiatives including Canadian and US corporate securities matters to support our listing on Nasdaq and delisting from TSX-V. Further, we incurred higher audit fees following our change of auditor to a US-based auditor. These increases were partially offset by a decrease in consulting fees due to realignment of our external resources to better support NVG-291 at its current phase of development.
·Investor and public relations expenses increased by $108,022 primarily due to an increase in stock exchange listing related fees following our listing on Nasdaq, which was partially offset by a decrease associated with investor and public relations activities around our CONNECT SCI topline data announcement which occurred during the nine months ended September 30, 2025.
·Employee salaries, bonuses, and benefits decreased by $861,862 primarily due to leadership changes over the last 12 months, including our appointment of a new CEO at a lower salary, and a bonus reversal in the current period related to the retirement of our former CFO, as well as the realignment of our personnel resources to better support NVG-291 at its current phase of development.
·Non-cash stock-based compensation expense increased by $1,665,779 primarily driven by option awards forfeited in the prior period upon termination of employment and services for several individuals within the general and administrative function, including our former CEO and former Chair of our board of directors.
·Other general and administrative expenses increased by $1,064,946 primarily due to an increase in Director and Officer insurance premiums as a result of our listing on Nasdaq, as well as an increase in employee recruitment efforts in the current period.

 

SUMMARY OF QUARTERLY FINANCIAL RESULTS

 

   Sep 30 2026   Jun 30 2026   Mar 31 2026   Dec 31 2025   Sep 30 2025   Jun 30 2025   Mar 31 2025   Dec 31 2024 
   $   $   $   $   $   $   $   $ 
Research & development   7,900,136    7,795,288    4,780,702    3,531,884    4,264,566    2,624,391    3,045,392    4,433,355 
General & administrative   3,287,750    4,066,560    2,476,183    2,590,215    1,296,146    3,298,105    2,637,260    1,625,439 
Net income (loss)   (6,408,493)   10,802,817    (1,925,425)   (26,491,752)   (4,718,275)   (8,998,617)   (4,005,689)   (7,781,618)
Basic income (loss) per share   (0.06)   0.12    (0.02)   (0.35)   (0.06)   (0.13)   (0.06)   (0.11)
Diluted income (loss) per share   (0.06)   (0.13)   (0.09)   (0.35)   (0.07)   (0.13)   (0.08)   (0.11)
Total assets   85,076,071    90,190,914    20,765,547    23,209,641    13,077,452    16,923,635    15,838,757    19,486,223 
Total liabilities   41,299,577    43,349,976    13,329,160    17,313,331    14,349,607    15,000,327    11,166,618    13,216,826 

 

Research and development expenses fluctuate based on clinical activities for NVG-291, preclinical evaluation of NVG-300, and the receipt of grant payments. Costs had risen steadily to the fourth quarter of 2024, due to the, then, ongoing Phase 1b/2a trials evaluating NVG-291. Enrollment for the chronic cohort was completed during the first quarter of 2025, and the last-patient-last-visit milestone was achieved in April 2025, triggering a grant milestone payment in the second quarter of 2025. Additionally, during the first quarter of 2025, we began enrolling the subacute cohort of the CONNECT SCI Study clinical trial. The wind-down of related clinical activities for the chronic cohort and receipt of the grant milestone were key drivers of lower expenses in the first and second quarter of 2025. During the third quarter of 2025 through the third quarter of 2026, CMC related expenditures were elevated as we manufactured materials for our Phase 3 clinical trial and future toxicology studies for NVG-291. Additionally, the first nine months of 2026 reflect costs related to the initiation of our Phase 3 clinical trial evaluating NVG-291 in chronic tetraplegia, as well as certain costs associated with nonclinical toxicology studies initiated in 2026.

 

General and administrative expenses consist of administrative activities related to expanding operations and developing staff and infrastructure. Expenses rose from the last three months of 2024 through the first six months of 2025 primarily due to increased salaries, bonus, benefits, and non-cash stock-based compensation reflecting higher headcount during those periods. Expenses declined significantly in the third quarter of 2025 as a result of the transition of our CEO and lower stock-based compensation expense due to option awards being forfeited upon termination of employment and services for several individuals within the general and administrative function, including our former CEO and former Chair of our board of directors. The increase in expenses during the fourth quarter of 2025 and through the third quarter of 2026 was primarily related to fees paid to external legal counsel in relation to Canadian and US corporate securities matters in connection with our Nasdaq listing and subsequent delisting from the TSX-V. Further, stock-based compensation contributed to the increase in expenses in the second quarter of 2026 as a result of initial awards granted to newly employed executive officers during the period, as well as incremental stock-based compensation expense recognized in relation to extension of post-termination exercise period for certain employees who retired during the period which did not recur in the three months ended September 30, 2026.

 

NERVGEN PHARMA CORP. 2026 Q3 MD&A10 

 

 

Net income (loss) includes non-cash unrealized gains and losses related to changes in the estimated fair value of the warrant derivative, determined using the Black-Scholes model. Fluctuations are related to changes in our share price, interest rates, and the foreign exchange rate between the Canadian and the U.S. dollar. The specific warrant securities underlying the liability also changed compared to the period prior to the fourth quarter of 2025. On November 19, 2025, pursuant to a non-brokered private placement, 4,785,674 units were sold at a purchase price of US$2.10 per unit. Each unit included one Common Share and one-half of one Common Share purchase warrant. Each whole warrant is exercisable into one Common Share at a price of US$2.65 per Common Share until November 19, 2028. The US dollar denominated warrants were recognized as a derivative financial liability recorded at fair value through profit or loss at initial recognition and in subsequent reporting periods. On December 12, 2025, we amended the terms of the warrants issued pursuant to the July 2022 non-brokered private placement, to change the denomination of the exercise price from US$1.75 to C$2.44. The change in the denomination of the exercise price resulted in the derecognition of the warrant derivative liability and recognition of an equity classified instrument at the fair value as determined on December 12, 2025. On May 22, 2026, pursuant to an underwritten public offering, 24,000,000 units were sold at a purchase price of US$2.50 per unit. Each unit included one Common Share and one Common Share purchase warrant. Each warrant is exercisable into one Common Share at a price of US$3.68 per Common Share until May 22, 2031. The US dollar denominated warrants were recognized as derivative financial liability recorded at fair value through profit or loss at initial recognition and in subsequent reporting periods. Share issuance costs of $3,920,232 allocated to the warrants were recognized immediately in profit or loss as finance costs, partially offsetting the non-cash gain on warrant derivative in the nine months ended September 30, 2026. The changes in fair value of the derivative liability have no cash flow impact. The net loss for the third quarter of 2026 included a non-cash unrealized gain on warrant derivative of $4,438,926.

 

LIQUIDITY AND CAPITAL RESOURCES

 

Since inception, we have devoted our resources to evaluating and securing intellectual property rights and licenses related to the technology licensed from CWRU; conducting discovery research; manufacturing drug supplies; performing preclinical studies and clinical trials; and providing administrative support to research and development activities. These efforts have supported the clinical development of NVG-291 and discovery of NVG-300, resulting in an accumulated deficit of $139,696,411 as of September 30, 2026. With current income only consisting of interest earned on excess cash in the amount of $581,415 for the three months ended September 30, 2026 (three months ended September 30, 2025 - $77,071) and $865,931 for the nine months ended September 30, 2026 (nine months ended September 30, 2025 - $271,736), losses are expected to continue while our research and development and clinical programs are advanced.

 

We do not earn any revenue from our product candidates and therefore are in the research and development stage. If our development efforts for our current or future product candidates are successful and result in regulatory approval or if we enter into additional license or collaboration agreements with third parties, we may generate revenue in the future from product sales, payments from such license or collaboration agreements, or any combination thereof. We cannot predict if, when or to what extent we will generate revenue as we may never succeed in obtaining regulatory approval for any of our product candidates. As required, we will continue to finance our operations through the issuance of equity and will pursue non-dilutive funding sources. The continuation of our research and development activities and the commercialization of our product candidates depends on our ability to successfully finance such activities through equity financings, grants and other non-dilutive sources, and possibly revenues from strategic partners. Until our product candidates are approved and available for sale, and profitable operations are developed, the extent of our progress on our research activities and future clinical trials and the related expenses will be dependent on our ability to continue to obtain adequate financing. We have no current sources of revenues from strategic partners.

 

On May 22, 2026, pursuant to an underwritten public offering, 24,000,000 units were sold at a purchase price of US$2.50 per unit for gross proceeds of $82.9 million (US$60.0 million). Each unit included one Common Share and one Common Share purchase warrant (the “May ‘26 Warrants”). Each warrant is exercisable into one Common Share at a price of US$3.68 per Common Share until May 22, 2031. There were 245 Common Shares sold under the ATM Program during the nine months ended September 30, 2026 for gross proceeds of $1,519, plus interest from the distribution agent. We incurred $50,510 in legal and professional fees related to maintaining and winding down the ATM Program.

 

NERVGEN PHARMA CORP. 2026 Q3 MD&A11 

 

 

On July 2, 2026, we filed a prospectus supplement that, together with the Base Shelf, qualified the distribution of up to US$50 million in Common Shares, under an at-the-market equity program (the “2026 ATM Program”) that allows us to issue and sell Common Shares to the public from time to time through an agent, at our discretion and subject to regulatory requirements. All Common Shares issued under the 2026 ATM Program will be sold through the Nasdaq, at the prevailing market price at the time of sale. As Common Shares distributed under the 2026 ATM Program will be issued and sold at the prevailing market prices at the time of their sale, prices may vary among purchasers and during the period of distribution. During the three months ended September 30, 2026, there were zero Common Shares issued and sold under the 2026 ATM Program and we incurred $323,279 of legal expenses and professional fees in connection with setting up the 2026 ATM Program.

 

During the three months ended September 30, 2026, we did not receive any proceeds from the exercise of warrants and $2,082,550 from the exercise of options. During the nine months ended September 30, 2026, we received $1,024,101 from the exercise of warrants and $4,966,237 from the exercise of options.

 

At September 30, 2026, we had a cash and cash equivalents balance of $80.1 million. Based upon our current operating plans we believe that our cash and cash equivalents as of September 30, 2026, will be sufficient to fund our operations for at least the next 12 months from September 30, 2026 and from the date of issuance of our condensed consolidated interim financial statements. We have based this projection on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. We will require additional capital to meet our announced goals (see “Company Overview” above for description of goals) and to fund our research and development plans including potential regulatory submissions and other future human clinical trials until we generate revenue that reaches a level sufficient to provide self-sustaining cash flows. While we have been successful in the past in obtaining financing, there can be no assurance that we will be able to obtain adequate financing, or that such financing will be available on terms acceptable to us, to meet future operational needs which may result in the delay, reduction, or discontinuation of ongoing or planned development programs.

 

The initiation of future clinical studies to evaluate NVG-291’s efficacy in indications other than chronic tetraplegia is subject to our ability to obtain additional funding and successfully enroll the required number of trial participants. The duration and cost of clinical trials can range significantly depending on a variety of factors including rate of enrollment, the country in which trials are conducted, and the specific trial protocol.

 

The following table presents a summary of our cash flows for the nine months ended September 30, 2026, and 2025:

 

   Nine Months Ended
September 30, 2026
   Nine Months Ended
September 30, 2025
 
   $   $ 
Net cash provided by (used in):          
Operating activities   (27,018,700)   (13,101,781)
Investing activities   8,411    75,695 
Financing activities   83,000,293    7,022,063 
Effect of foreign exchange on cash and cash equivalents   2,060,271    100,589 
Net (decrease) increase in cash and cash equivalents   58,050,275    (5,903,434)

 

Cash used in operating activities:

 

Our uses of cash for operating activities for the nine months ended September 30, 2026, and 2025 consisted of costs associated with the initiation of our Phase 3 clinical trial evaluating NVG-291 in chronic tetraplegia, CMC costs to support clinical and non-clinical activities, non-clinical toxicology studies, professional fees, salaries and wages for our employees, and Phase 1b/2a clinical trial costs.

 

Cash from investing activities:

 

Cash generated from investing activities in the nine months ended September 30, 2026, and 2025 relate to the sub-sublease of our office space.

 

Cash from financing activities:

 

During the nine months ended September 30, 2026, funds were received from the exercise of 357,422 warrants for total cash proceeds of $1,024,101, and from the exercise of 4,045,000 options at varying exercise prices per Common Share for total cash proceeds of $4,966,237. Of the options exercised, 535,009 shares were withheld on net settlement, resulting in 3,509,991 Common Shares issued. We also issued and sold 245 Common Shares under the ATM Program at a weighted average price of $6.20 per unit, for aggregate gross proceeds of $1,519, plus interest from the distribution agent. We incurred cash placement fees and professional fees totaling $50,510 related to maintaining and winding down the ATM Program. Further, on May 22, 2026, pursuant to an underwritten public offering, 24,000,000 units were sold at a purchase price of US$2.50 per unit for gross proceeds of $82.9 million (US$60 million). Each unit included one Common Share and one Common Share purchase warrant (the “May ‘26 Warrants”). Each warrant is exercisable into one Common Share at a price of US$3.68 per Common Share until May 22, 2031

 

NERVGEN PHARMA CORP. 2026 Q3 MD&A12 

 

 

During the nine months ended September 30, 2025, funds were received from the exercise of 925,441 warrants for total cash proceeds of $2,758,796 and from the exercise of 1,199,503 options at varying exercise prices per Common Share for total cash proceeds of $2,250,080. We also issued and sold 949,700 Common Shares under the ATM Program at a weighted average price of $2.92 per unit, for aggregate gross proceeds of $2,774,227. We paid cash placement fees of $55,485 to the agents resulting in aggregate net proceeds of $2,718,742. We also incurred $629,859 in professional fees to establish and maintain the ATM Program, including $410,255 that were incurred in 2024.

 

CASH POSITION

 

At September 30, 2026, we had a cash and cash equivalents balance of $80,119,910 compared to $22,069,635 at December 31, 2025. The funds expended during the nine months ended September 30, 2026, for operating activities (including the effect of foreign exchange on cash and cash equivalents), of $24,958,429 (September 30, 2025 - $13,001,193), were used to fund operating expenditures for the initiation of our Phase 3 clinical trial evaluating NVG-291 in chronic tetraplegia, drug product formulation, development and manufacturing, salaries and benefits, clinical costs associated with the CONNECT SCI Study, and fees paid in connection with preclinical studies.

 

We invest cash in excess of current operational requirements in highly rated and liquid instruments.

 

Working capital (a non-GAAP measure defined as current assets less current liabilities on our condensed consolidated interim statements of financial position) as of September 30, 2026 was positive $43,409,177 (September 30, 2025 – negative $1,695,267). Our current liabilities include $34,623,324 related to the non-cash warrant derivative. Given the nature of this liability, no funds would ever be expended by us, and it does not represent a liquidity risk. We believe our current cash resources are sufficient to fund planned operations and capital requirements for at least the next 12 months from September 30, 2026 and from the date of issuance of our condensed consolidated interim financial statements. Future capital requirements will depend on a number of factors, including the progress of development activities, business development opportunities, and market conditions. We may seek additional funding through equity financings, strategic partnerships, grant funding, or other financing arrangements as needed. There can be no assurance that such funding will be available on acceptable terms, if at all.

 

We do not expect to generate positive cash flow from operations for the foreseeable future due to additional expenses involved in commercializing our technologies, including expenses related to drug discovery, preclinical testing, clinical trials, CMC, regulatory activities and operating expenses associated with supporting these activities. We expect that negative cash flow from operations will continue until such time, if ever, that we receive regulatory approval to commercialize any of our product candidates under development and/or royalty or milestone revenue from the licensing of any such product candidates should they exceed our expenses.

 

CONTRACTUAL OBLIGATIONS

 

We enter into research, development and license agreements in the ordinary course of business where we receive research services and rights to proprietary technologies. These contracts are typically cancellable by the Company with notice. Milestone and royalty payments or grant funding repayments that may become due under various agreements are dependent on, among other factors, clinical trials, regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which is uncertain. In addition, we incur purchase obligations in the ordinary course of business for clinical trials, drug manufacturing, nonclinical studies, stability and other related costs that can include payments over a number of months due to the nature of these activities. The amounts in the table below represent the contractual amounts under the agreements in place as of September 30, 2026, and do not represent the costs anticipated to complete specific Company objectives. We expect that these commitments will continue to increase in frequency and value as we continue to execute our business plan.

 

Under the exclusive worldwide licensing agreement with CWRU to research, develop and commercialize patented technologies, we have commitments to pay various annual license fees, patent costs, milestone payments and royalties on revenues, contingent on the achievement of certain development and regulatory milestones. We cannot reasonably estimate milestone payments that are contingent upon the occurrence of future events or future royalties which may be due upon the regulatory approval of products derived from licensed technologies. Pursuant to the license agreement, all the key patents for NVG-291 are owned by CWRU and licensed to the Company.

 

NERVGEN PHARMA CORP. 2026 Q3 MD&A13 

 

 

As of September 30, 2026, we are obligated to pay the following to CWRU:

 

•An annual minimum royalty of US$50,000 per year, adjusted by the cumulative percent change in the CPI-W.
•Project milestones payable based on the achievement of future clinical development milestones, up to US$1,885,000, of which US$135,000 has been paid related to milestones achieved as of September 30, 2026. There are up to US$1,750,000 remaining milestone payments as of September 30, 2026. Subsequent to September 30, 2026, certain clinical development milestones were achieved triggering a milestone of US$250,000 to be payable.

 

Other than as disclosed below, we did not have any contractual obligations relating to long-term debt obligations, capital (finance) lease obligations, operating lease obligations, purchase obligations or other long-term liabilities reflected on our condensed consolidated interim statements of financial position as of September 30, 2026:

 

Anticipated Commitments  Under 1 Year   1-3 Years   4-5 Years   Total 
   $   $   $   $ 
Patent licensing costs, minimum annual royalties per license agreements   93,976    187,953    93,976    375,905 
Purchase obligations   3,492,066    -    -    3,492,066 

 

In addition, in June 2023, the Company was awarded a grant of up to US$3.18 million (C$4.22 million) to support the Company’s Phase 1b/2a CONNECT SCI Study in individuals with SCI. In connection with the grant, the Company has agreed to pay a percentage of the Company’s net annual sales revenue of NVG-291, or any derivative approved in SCI through the provision of an unrestricted donation to the granting entity in the amount of up to the total funds received through the agreement. Any donation that may become due under the agreement is dependent on, among other factors, the successful development and sale of a new drug, the outcome and timing of which is uncertain. As of September 30, 2026, the grant had concluded and the Company had received US$2.56 million (C$3.40 million) over the life of the grant. There are no future proceeds expected to be received under this grant. The grant funding received was recorded as a reduction of the related clinical and regulatory expenses, included in research and development expenses, in the period the milestone was earned.

 

OFF-BALANCE SHEET ARRANGEMENTS

 

We have no material undisclosed off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our results of operations, financial condition, revenues or expenses, liquidity, capital expenditures or capital resources that are material to investors.

 

TRANSACTIONS WITH KEY MANAGEMENT PERSONNEL

 

Key management personnel, consisting of the Company’s Board of Directors and corporate officers, received the following compensation for the following periods: 

 

   Three Months
Ended
September 30,
2026
   Three Months
Ended
September 30,
2025
(Restated)
   Nine Months
Ended
September 30,
2026
   Nine Months
Ended
September 30,
2025
(Restated)
 
   $   $   $   $ 
Stock-based compensation   958,637    392,597    2,835,703    1,865,408 
Salaries and bonuses   413,863    264,784    752,591    1,728,381 
Consulting fees   29,398    214,613    236,942    214,613 
    1,401,898    871,994    3,825,236    3,808,402 

 

As at September 30, 2026, we had amounts owing or accrued to key management personnel of $236,222 (December 31, 2025 - $332,430) pertaining to accrued bonus, consulting services, and expense reimbursements.

 

NERVGEN PHARMA CORP. 2026 Q3 MD&A14 

 

 

MATERIAL ACCOUNTING POLICIES, BASIS OF PRESENTATION AND CRITICAL ACCOUNTING ESTIMATES

 

Material Accounting Policies:

 

Material accounting policies are described in Note 3 of the audited consolidated financial statements for the year ended December 31, 2025, and available on SEDAR+ (www.sedarplus.ca) and included in our Annual Report on Form 40-F/A for the year ended December 31, 2025 (the “Form 40-F/A”) filed with the SEC on October 16, 2026.

 

Basis of Presentation:

 

The condensed consolidated interim financial statements have been prepared in accordance with IFRS accounting standards applicable to a going concern using the historical cost basis. The Company is in pre-revenue stage and no revenues are expected in the foreseeable future. Our future operations are dependent on the success of our ongoing development, as well as our ability to secure additional financing as needed. We have forecasted that our existing working capital is sufficient to operate for at least the next 12 months from September 30, 2026 and from the date of issuance of the condensed consolidated interim financial statements. We have based this projection on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. We will need to raise additional capital to fund our research and development plans including potential regulatory submissions and other future clinical trials until we generate revenue that reaches a level sufficient to provide self-sustaining cash flows. While we have been successful in the past in obtaining financing, there can be no assurance that we will be able to obtain adequate financing, or that such financing will be on terms acceptable to us to meet future operational needs which may result in the delay, reduction, or discontinuation of ongoing development programs.

 

Critical Accounting Estimates:

 

Estimates and assumptions are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The determination of estimates requires the exercise of judgement based on various assumptions and other factors such as historical experience and current and expected economic conditions. Actual results could differ from those estimates. Significant assumptions about the future and other sources of estimation uncertainty that we have made at the condensed consolidated interim statements of financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities include:

 

Intangible assets

 

We estimate the useful lives of intangible assets from the date they are available for use in the manner intended by management and periodically review the useful lives to reflect management’s intent about developing and commercializing the assets.

 

Government Assistance

 

Management considers the reasonableness of whether we have met the requirements of the approved government assistance and whether there is reasonable assurance that the amount will be received. Government assistance can be subject to audits so the amounts received may differ from the amounts recorded.

 

Warrant derivative

 

We estimate the fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period. This estimate requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility, and dividend yield, and making assumptions about them.

 

Valuation of stock-based compensation and warrants

 

We measure the costs for stock-based compensation and warrants using market-based option valuation techniques. Assumptions are made and estimates are used in applying the valuation techniques. These include estimating the future volatility of the share price, expected dividend yield, expected risk-free interest rate, future employee turnover rates, and expected term. Such estimates and assumptions are inherently uncertain. Changes in these assumptions affect the fair value estimates of stock-based compensation and warrants.

 

Functional currency

 

We consider the determination of the functional currency of the Company a significant judgment. We have used our judgment to determine the functional currency that most faithfully represents the economic effects of the underlying transactions, events and conditions and considered various factors including the currency of historical and future expenditures and the currency in which funds from financing activities are generated. A Company’s functional currency is only changed when there is a material change in the underlying transactions, events and conditions.

 

NERVGEN PHARMA CORP. 2026 Q3 MD&A15 

 

 

Going concern

 

Our assessment of our ability to continue as a going concern requires judgments about whether there are events or conditions that may cast significant doubt about our ability to continue as a going concern. We have determined that the use of the going concern basis of accounting is appropriate.

 

FINANCIAL INSTRUMENTS

 

(a) Fair value

 

Financial instruments are classified into one of the following categories: fair value through profit or loss (“FVTPL”); fair value through other comprehensive income; or amortized cost. The carrying values of our financial instruments are classified into the following categories:

 

      September 30, 2026   December 31, 2025 
Financial Instrument  Category  $   $ 
Cash and cash equivalents  FVTPL   80,119,910    22,069,635 
Accounts receivable  Amortized cost   111,953    80,825 
Net investment in lease  Amortized cost   -    8,369 
Warrant derivative  FVTPL   34,623,324    12,647,514 
Accounts payable and accrued liabilities  Amortized cost   6,676,251    4,657,448 

 

Our financial instruments, recorded at fair value, require disclosure about how the fair value was determined based on significant levels of inputs described in the following hierarchy:

 

  Level 1 - Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions occur in sufficient frequency and value to provide pricing information on an ongoing basis.

 

  Level 2 - Pricing inputs are other than quoted prices in active markets included in Level 1. Prices in Level 2 are either directly or indirectly observable as of the reporting date. Level 2 valuations are based on inputs including quoted forward prices for commodities, time value and volatility factors, which can be substantially observed or corroborated in the marketplace.

 

  Level 3 - Valuations in this level are those with inputs for the asset or liability that are not based on observable market data.

 

Cash and cash equivalents are measured at fair value using Level 1 as the basis for measurement in the fair value. The recorded amounts for accounts receivable, accounts payable and accrued liabilities, approximate their fair value due to their short-term nature. In July 2022, November 2025, and May 2026, we issued Common Share purchase warrants with an exercise price denominated in a currency that differs from our functional currency, which were treated as a derivative measured at fair value with subsequent changes in fair value accounted for through the consolidated statements of income (loss) and comprehensive income (loss). The warrants issued in July 2022 were subsequently amended in December 2025 to have an exercise price denominated in our functional currency resulting in a reclassification of the warrant as an equity classified instrument at the fair value determined on the date of the amendment. The November 2025 and May 2026 warrants remain liability classified as of September 30, 2026, and the fair value of our warrant derivative recognized on the consolidated statements of financial position is based on level 2 inputs (significant observable inputs) as these warrants have not been listed on an exchange and therefore do not trade on an active market. As of September 30, 2026, the fair value of our non-cash warrant derivative was $34,623,324 (December 31, 2025 - $12,647,514). We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility, the risk-free interest rate is based on Federal Reserve Bank of St. Louis benchmark treasury yield rates and the expected life represents the estimated length of time the warrants are expected to remain outstanding.

 

NERVGEN PHARMA CORP. 2026 Q3 MD&A16 

 

 

(b) Financial risk management

 

Our risk exposures and the impact on our consolidated financial instruments are summarized below. Our Board has the overall responsibility for the oversight of these risks and reviews our policies on an ongoing basis to ensure that these risks are appropriately managed.

 

i.Liquidity Risk

 

Liquidity risk is the risk that we will not have the resources to meet our obligations as they fall due. We manage this risk by closely monitoring cash forecasts and managing resources to ensure that we will have sufficient liquidity to meet our obligations. All of our financial liabilities are classified as current and the majority, other than the non-cash warrant derivative, are anticipated to mature within the next ninety days. We are exposed to liquidity risk other than for the warrant derivative which is non-cash.

 

ii.Credit Risk

 

Credit risk is the risk of potential loss if a counterparty to a financial instrument fails to meet its contractual obligations. Our credit risk is primarily attributable to our liquid financial assets, including cash and cash equivalents, receivables, deposits, and balances receivable from the government. We limit the exposure to credit risk in our cash and cash equivalents by only holding our cash and cash equivalents with high-credit quality financial institutions in business and/or savings accounts.

 

iii.Market Risk

 

Market risk is the risk of loss that may arise from changes in market factors such as interest rates, foreign exchange rates, and equity prices. These fluctuations may be significant.

 

(a) Foreign Currency Risk:

 

We have identified our functional currency as the Canadian dollar. Transactions are transacted in Canadian dollars, U.S. dollars and in Australian dollars. Fluctuations in the U.S. or Australian dollar exchange rate could have a significant impact on the Company’s results. Assuming all other variables remain constant, a 10% depreciation or appreciation of the Canadian dollar against the U.S. dollar would result in an increase or decrease in net income (loss) and comprehensive income (loss) for the nine months ended September 30, 2026, of $7.2 million (September 30, 2025 - $0.1 million). A 10% depreciation or appreciation of the Canadian dollar against the Australian dollar would result in an increase or decrease in net income (loss) and comprehensive income (loss) for the nine months ended September 30, 2026, of $0.2 million (September 30, 2025 - $0.1 million).

 

In the near-term, we mitigate overall currency risk through the use of U.S. dollar denominated cash balances to pay forecasted U.S. denominated expenses when possible. In the long-term, we are exposed to net currency risk from employee costs as well as the purchase of goods and services in the United States and Australia.

 

Balances in U.S. dollars are as follows:

 

   September 30, 2026   December 31, 2025 
   ($US)   ($US) 
Cash   51,074,348    9,695,348 
Receivables   75,390    47,275 
Vendor deposits   2,662,670    134,503 
Accounts payable and accrued liabilities   (3,062,685)   (1,331,795)
    50,749,721    8,545,331 

 

Balances in Australian dollars are as follows:

 

   September 30, 2026   December 31, 2025 
   ($ AUD)   ($ AUD) 
Cash   420,134    529,628 
Accounts receivable   1,087    2,036 
Accounts payable and accrued liabilities   (2,026,906)   (2,009,171)
    (1,605,685)   (1,477,507)

 

NERVGEN PHARMA CORP. 2026 Q3 MD&A17 

 

 

(b) Interest Rate Risk

 

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The warrant derivative that is discussed further in Note 14 of the September 30, 2026 condensed consolidated interim financial statements is recorded at fair value using a Black-Scholes pricing model with changes in fair value recorded in the condensed consolidated interim statements of income (loss) and comprehensive income (loss). An input to the model is the risk-free rate which is reflective of US treasury yields. Therefore, we are exposed to interest rate risk through the non-cash impact it has on the condensed consolidated interim statements of income (loss) and comprehensive income (loss). Additionally, we are exposed to interest rate risk from cash and cash equivalents held in interest bearing accounts. We maintain our cash balances in highly liquid deposit accounts with reputable financial institutions. These balances are generally held to meet short-term operational and liquidity requirements and are invested in instruments with short maturities to preserve capital and maintain liquidity. As a result, our exposure to fluctuations in interest rates is limited and relates primarily to changes in interest income earned on variable-rate cash deposits. We monitor prevailing market conditions and interest rates on an ongoing basis. Given the short-term and highly liquid nature of the Company's cash and cash equivalent balances, the fair value of these instruments approximates their carrying value.

 

(c) Other Price Risk

 

Other price risks include the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than interest rate or currency risk). The warrant derivative that is discussed further in Note 14 of the September 30, 2026 condensed consolidated interim financial statements is recorded at fair value using a Black-Scholes pricing model with changes in fair value recorded in the condensed consolidated interim statements of income (loss) and comprehensive income (loss). An input to the model is the market price of the Company’s shares as of the valuation date. Therefore, we are exposed to other price risk through the non-cash impact it has on the condensed consolidated interim statements of income (loss) and comprehensive income (loss).

 

(c) Managing capital

 

Our objectives, when managing capital, are to safeguard cash and cash equivalents as well as maintain financial liquidity and flexibility in order to preserve our ability to meet financial obligations and deploy capital to grow our business.

 

Our financial strategy is designed to maintain a flexible capital structure consistent with the objectives stated above and to respond to business growth opportunities and changes in economic conditions. In order to maintain or adjust our capital structure we may issue shares or issue debt (secured, unsecured, convertible and/or other types of available debt instruments).

 

On November 25, 2024, the Company filed a short form base shelf prospectus, which was subsequently amended and restated on December 15, 2025, further amended on May 22, 2026 (the “Base Shelf”) that qualifies for distribution of up to US$250,000,000 of Common Shares, debt securities, subscription receipts, warrants and units comprised of one or more of the other securities described. The Base Shelf amends and restates our previous base shelf and was also registered with the SEC and included in the Registration Statement (also collectively the “Base Shelf”). Under our Base Shelf, we may sell securities to or through underwriters, dealers, placement agents, or other intermediaries, and also may sell securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying prospectus supplement.

 

Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Our amended Base Shelf will be effective until December 25, 2026.

 

NERVGEN PHARMA CORP. 2026 Q3 MD&A18 

 

 

On December 19, 2024, we filed a prospectus supplement that, together with the Base Shelf, qualified the distribution of Common Shares under the ATM Program that allowed the Company to issue and sell Common Shares to the public from time to time through an agent, at our discretion and subject to regulatory requirements. All Common Shares sold under the ATM Program were sold through the TSX Venture Exchange, at the prevailing market price at the time of sale. On March 12, 2026, we terminated the ATM Program concurrently with the announcement of our voluntary delisting from the TSX-V. Common Shares distributed under the ATM Program were issued and sold at the prevailing market prices at the time of their sale, and prices varied among purchasers and during the period of distribution.

 

During the nine months ended September 30, 2026, we issued and sold 245 Common Shares under the ATM Program at a weighted average price of $6.20 per Common Share, for aggregate gross proceeds of $1,519, plus interest from the distribution agent. We incurred cash placement fees and professional fees totaling $50,510 related to maintaining and winding down the ATM Program. These costs are recorded as a decrease to Common Shares within the condensed consolidated statements of financial position.

 

On July 2, 2026, we filed a prospectus supplement that, together with the Base Shelf, qualified the distribution of up to US$50 million in Common Shares under the 2026 ATM Program, which allows us to issue and sell Common Shares to the public from time to time through an agent, at our discretion and subject to regulatory requirements. All Common Shares issued under the 2026 ATM Program will be sold through the Nasdaq, at the prevailing market price at the time of sale. As Common Shares distributed under the 2026 ATM Program are issued and sold at the prevailing market prices at the time of their sale, prices may vary among purchasers and during the period of distribution. During the nine months ended September 30, 2026, we issued and sold zero Common Shares under the 2026 ATM Program and incurred $323,279 of legal expenses and professional fees in connection with setting up the 2026 ATM Program.

 

There were no changes to our capital management policy during the period. We are not subject to any externally imposed capital requirements.

 

USE OF PROCEEDS

 

2026 ATM Offering

 

As of the date of this report, the Company has not issued or sold any Common Shares under the 2026 ATM Program and, accordingly, has not received any proceeds from the 2026 ATM Program. As disclosed in the Company’s prospectus supplement dated July 2, 2026, which qualified the distribution of up to US$50 million in Common Shares, the principal business objectives that management expects to accomplish using the net proceeds from the 2026 ATM Program, if any, are to fund general corporate purposes including to fund ongoing operations and/or working capital requirements, to repay indebtedness outstanding from time to time, to fund research and development, intellectual property development, and preclinical and clinical expenses. In addition, management of the Company has broad discretion with respect to the actual use of the net proceeds from the 2026 ATM Program.

 

May 2026 Underwritten Public Offering

 

The following table provides an update on the use of net proceeds raised in the May 2026 underwritten public offering as disclosed in the Company’s prospectus supplement dated May 22, 2026, along with actual amounts expended (in

millions of US dollars):

 

Principal Purpose  Estimated Amount to
be Expended
   Actual Amount
Expended
   Remaining Amount
to be Expended
 
Phase 3 RESTORE registrational study of NVG-291   40.0    0.2    39.8 
General corporate and working capital purposes   16.0    -    16.0 
Balance September 30, 2026   56.0    0.2    55.8 

 

November 2025 Non-brokered Private Placement

 

The principal business objectives that management expects to accomplish using the net proceeds from the November 2025 non-brokered private placement, are advancing the Company’s NVG-291 clinical development program and for general corporate purposes, including to fund ongoing operations and/or working capital requirements, to repay indebtedness outstanding from time to time, or for other corporate purposes.

 

NERVGEN PHARMA CORP. 2026 Q3 MD&A19 

 

 

2025 ATM Offering

 

As of the date of this report, the Company has raised total net proceeds of approximately $2.1 million, which has been used to fund ongoing operations and working capital requirements. As disclosed in the Company’s prospectus supplement dated December 19, 2024, the principal business objectives that management expected to accomplish using the net proceeds from the ATM Program, were to fund general corporate purposes including to fund ongoing operations and/or working capital requirements, to repay indebtedness outstanding from time to time, to complete future acquisitions, to fund research and development, intellectual property development, preclinical expenses, or for other corporate purposes. In addition, management of the Company has broad discretion with respect to the actual use of the net proceeds from the ATM offering. On March 12, 2026, we terminated the ATM Program concurrently with the announcement of our voluntary delisting from the TSX-V.

 

DISCLOSURE OF OUTSTANDING SHARE DATA

 

The following details the share capital structure as of the last business date immediately preceding the date of this MD&A:

 

   Common
Shares Issued
and
Outstanding
   Warrants
Issued and
Outstanding
   Common
Share
Purchase
Options
   Retention
Securities
   Performance
Share Units
 
Balance December 31, 2025   79,649,257    11,339,848    9,275,900    491,667    - 
Balance September 30, 2026   107,616,412    34,982,426    8,459,527    -    308,568 
Balance November 13, 2026   107,616,412    34,982,426    8,489,527    -    308,568 

 

MANAGEMENT’S RESPONSIBILITY FOR THE FINANCIAL STATEMENTS

 

The Company’s certifying officers, based on their knowledge, having exercised reasonable diligence, are responsible to ensure that these filings do not contain any untrue statement of material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by these filings, and these condensed consolidated interim financial statements together with the other financial information included in these filings. The Board approved the condensed consolidated interim financial statements and MD&A and ensures that management has discharged its financial responsibilities.

 

RISKS AND UNCERTAINTIES

 

An investment in the Common Shares of NervGen involves a high degree of risk and should be considered speculative. An investment in the Common Shares should only be undertaken by those persons who can afford the total loss of their investment. Investors should carefully consider the risks and uncertainties set forth under the heading “Risk Factors” found in the AIF, as well as other information described elsewhere in this MD&A. Additional risks and uncertainties not presently known to us or that we believe to be immaterial may also adversely affect our business. If any such risks occur, our business, financial condition and results of operations could be seriously harmed, and you could lose all or part of your investment. Further, if we fail to meet the expectations of the public market in any given period, the market price of our Common Shares could decline. We operate in a highly competitive environment that involves significant risks and uncertainties, some of which are outside of our control.

 

SUBSEQUENT EVENTS

 

Subsequent to September 30, 2026 the Company:

 

(a)       achieved a clinical development milestone upon the dosing of the first participant in RESTORE, our Phase 3 registrational trial evaluating NVG-291 in chronic tetraplegia, triggering a milestone payment to CWRU of US$250,000.

 

NERVGEN PHARMA CORP. 2026 Q3 MD&A20 

 

 

DISCLOSURE CONTROLS AND PROCEDURES AND INTERNAL CONTROLS OVER FINANCIAL REPORTING

 

Because of the material weakness described below, the CEO and Chief Financial Officer (“CFO”) concluded that the Company’s disclosure controls and procedures (“DC&P”) and internal control over financial reporting (“ICFR”) were not effective as of September 30, 2026.

 

Material weakness

 

A material weakness is a deficiency, or a combination of deficiencies, in ICFR such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis.

 

Management identified a material weakness in the design of the Company's controls over the review of the calculation of the share option and warrant derivative values, and classification of share-issuance costs. Specifically, (i) the management review control did not identify an error in a spreadsheet formula used to calculate annualized volatility, a key input in the Black-Scholes valuation model; and (ii) responsibility for preparing and reviewing complex accounting matters was concentrated in a small number of finance personnel, which reduced the attention available to prepare and review these estimates and did not provide sufficient segregation of duties. As a result, the error was not detected on a timely basis and resulted in a material misstatement in the Company's previously issued financial statements.

 

Impact

 

The material weakness resulted in misstatements of warrant derivative liabilities, unrealized gains and losses on warrant derivatives, stock-based compensation expense, the expensing of share issuance costs, common shares in equity, stock-based payment reserve in equity, and accumulated deficit in equity, in the Company’s previously issued financial statements. The Company has restated its audited annual financial statements for the year ended December 31, 2025, including the 2024 comparative figures and the January 1, 2024 opening balances, and its unaudited condensed consolidated interim financial statements for the three and six months ended June 30, 2026 and 2025. The restatement was non-cash and does not affect the Company’s cash, cash equivalents or cash runway. Management has not identified misstatements in other accounts, however, the material weakness could result in a misstatement of these accounts or related disclosures that would cause a material misstatement of the annual or interim financial statements that would not be prevented or detected on a timely basis.

 

Remediation

 

Management, with the oversight of the Audit Committee, has taken or is taking the following actions:

 

·The Company prepared a documented valuation methodology memo that addresses how key inputs, including expected volatility, are derived. The memo was prepared by the Company’s Accounting Manager, reviewed by the Corporate Controller, and implemented effective for the period ended September 30, 2026, and is applied in each valuation.
·The Company hired an Accounting Manager, who started on October 5, 2026 and prepared the valuations of options and warrants as at September 30, 2026. The Corporate Controller reviews each valuation, including an independent recalculation of key inputs.
·The Company is evaluating an equity management system to serve as the system of record for equity and warrant instruments.
·The Company hired a Director of Contracts, who started on August 12, 2026 and assumed responsibilities previously performed by the Corporate Controller. This was intended to give the finance team more capacity and a better segregation of duties for complex accounting matters.

 

Timing

 

Management will consider the material weakness remediated when the new controls have operated effectively for a sufficient period and management has concluded, through testing, that they are operating effectively. The Company cannot assure when remediation will be complete.

 

Changes in internal control over financial reporting

 

Management is implementing the remediation measures described above. Other than the changes previously noted, there were no other changes in ICFR during the three months ended September 30, 2026 that materially affected, or are reasonably likely to materially affect, ICFR.

 

OTHER INFORMATION

 

Additional information relating to the Company, including our most recently filed AIF, is available for viewing on our website at www.nervgen.com, and under our profile on SEDAR+ at www.sedarplus.ca, and included in our Form 40-F/A filed with the SEC.

 

NERVGEN PHARMA CORP. 2026 Q3 MD&A21 

 

 

Exhibit 99.3

 

 

Form 52-109F2

Certification of Interim Filings

Full Certificate

 

I, Adam Rogers, Chief Executive Officer of NervGen Pharma Corp., certify the following:

 

1.Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of NervGen Pharma Corp. (the “issuer”) for the interim period ended September 30, 2026.

 

2.No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

 

3.Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

 

4.Responsibility: The issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings, for the issuer.

 

5.Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer(s) and I have, as at the end of the period covered by the interim filings

 

(a)designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

 

(i)material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

 

(ii)information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

 

(b)designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.

 

1

 

 

5.1Control framework: The control framework the issuer’s other certifying officer(s) and I used to design the issuer’s ICFR is Internal control - Integrated Framework (COSO 2013 Framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

 

5.2ICFR – material weakness relating to design: The issuer has disclosed in its interim MD&A for each material weakness relating to design existing at the end of the interim period

 

(a)a description of the material weakness;

 

(b)the impact of the material weakness on the issuer’s financial reporting and its ICFR; and

 

(c)the issuer’s current plans, if any, or any actions already undertaken, for remediating the material weakness.

 

5.3N/A

 

6.Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer’s ICFR that occurred during the period beginning on July 1, 2026 and ended on September 30, 2026 that has materially affected, or is reasonably likely to materially affect, the issuer’s ICFR.

 

Date: November 16, 2026

 

/s/ “Adam Rogers”  
Adam Rogers  
Chief Executive Officer  

 

2

 

 

Exhibit 99.4

 

 

Form 52-109F2

Certification of Interim Filings

Full Certificate

 

I, Keith Vendola, Chief Financial Officer of NervGen Pharma Corp., certify the following:

 

1.Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of NervGen Pharma Corp. (the “issuer”) for the interim period ended September 30, 2026.

 

2.No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

 

3.Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

 

4.Responsibility: The issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings, for the issuer.

 

5.Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer(s) and I have, as at the end of the period covered by the interim filings

 

(a)designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

 

(i)material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

 

(ii)information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

 

(b)designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.

 

1

 

 

5.1Control framework: The control framework the issuer’s other certifying officer(s) and I used to design the issuer’s ICFR is Internal control - Integrated Framework (COSO 2013 Framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

 

5.2ICFR – material weakness relating to design: The issuer has disclosed in its interim MD&A for each material weakness relating to design existing at the end of the interim period

 

(a)a description of the material weakness;

 

(b)the impact of the material weakness on the issuer’s financial reporting and its ICFR; and

 

(c)the issuer’s current plans, if any, or any actions already undertaken, for remediating the material weakness.

 

5.3N/A

 

6.Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer’s ICFR that occurred during the period beginning on July 1, 2026 and ended on September 30, 2026 that has materially affected, or is reasonably likely to materially affect, the issuer’s ICFR.

 

Date: November 16, 2026

 

/s/ “Keith Vendola”  
Keith Vendola  
Chief Financial Officer  

 

2

 

Filing Exhibits & Attachments

4 documents

Keep reading